,id,pubMedId,title,url,Treatment_id
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,1
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,1
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,1
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,7
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,33
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,36
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,40
0,514,16556909,Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.,http://www.ncbi.nlm.nih.gov/pubmed/16556909,42
0,520,23881923,"BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.",http://www.ncbi.nlm.nih.gov/pubmed/23881923,43
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,45
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,46
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,47
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,48
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,49
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,50
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,51
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,58
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,69
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,69
0,537,24893891,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24893891,71
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,81
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,81
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,81
0,9560,26260909,Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26260909,82
1,9561,24367169,Lapatinib: new opportunities for management of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24367169,82
0,9557,28520362,,http://www.ncbi.nlm.nih.gov/pubmed/28520362,102
1,9558,28520364,,http://www.ncbi.nlm.nih.gov/pubmed/28520364,102
2,9559,25398397,"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.",http://www.ncbi.nlm.nih.gov/pubmed/25398397,102
0,651,24317392,"A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/24317392,107
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,120
0,770,20609467,Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.,http://www.ncbi.nlm.nih.gov/pubmed/20609467,138
0,286,,FDA.gov,http://www.fda.gov/,154
0,333,17483355,"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.",http://www.ncbi.nlm.nih.gov/pubmed/17483355,159
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,168
0,2493,25668228,EGFR T790M resistance mutation in non small-cell lung carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25668228,170
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,177
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,178
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,179
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,183
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,184
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,185
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,186
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,187
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,188
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,189
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,190
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,191
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,192
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,193
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,194
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,195
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,203
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,204
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,205
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,206
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,207
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,208
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,209
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,210
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,211
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,212
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,213
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,214
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,215
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,216
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,217
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,218
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,219
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,220
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,221
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,222
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,223
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,224
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,225
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,226
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,261
1,1847,25568876,Clinical advances in the development of novel VEGFR2 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25568876,261
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,263
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,264
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,270
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,271
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,272
1,1847,25568876,Clinical advances in the development of novel VEGFR2 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25568876,272
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,273
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,273
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,273
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,274
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,274
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,274
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,275
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,275
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,275
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,378
1,1847,25568876,Clinical advances in the development of novel VEGFR2 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25568876,378
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,379
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,380
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,380
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,380
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,381
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,381
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,381
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,382
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,382
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,382
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,383
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,384
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,385
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,386
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,389
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,390
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,391
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,392
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,393
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,394
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,395
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,396
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,397
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,398
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,399
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,400
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,401
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,402
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,403
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,404
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,405
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,406
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,407
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,408
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,409
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,410
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,411
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,412
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,413
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,414
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,415
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,416
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,417
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,418
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,419
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,420
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,421
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,422
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,423
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,430
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,430
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,434
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,435
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,435
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,447
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,448
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,464
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,464
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,465
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,465
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,466
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,466
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,466
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,467
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,467
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,470
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,471
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,472
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,473
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,474
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,476
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,477
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,478
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,497
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,498
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,539
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,539
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,539
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,543
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,544
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,544
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,605
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,605
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,610
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,703
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,703
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,705
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,706
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,707
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,708
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,709
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,710
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,711
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,712
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,713
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,714
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,715
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,716
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,717
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,718
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,726
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,726
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,727
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,728
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,729
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,730
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,731
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,732
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,733
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,734
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,735
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,736
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,900
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,901
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,902
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,903
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,903
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,904
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,904
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,908
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1175
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1176
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1177
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1178
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1179
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1180
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1181
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1182
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1183
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1184
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1185
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1186
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1187
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1188
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1189
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1190
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1191
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1192
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1193
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1194
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1195
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1196
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1197
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1198
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1199
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1200
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1201
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1202
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1203
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,1223
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,1223
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,1223
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1224
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1225
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,1226
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,1226
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,1226
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,1227
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,1227
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,1227
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1228
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1228
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1229
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1229
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1231
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1231
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1232
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1232
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1233
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1233
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1234
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1234
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1235
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1236
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1237
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1237
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1239
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1239
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1241
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1241
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1242
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1243
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1244
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1245
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1246
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1247
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1273
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1274
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1472
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1472
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1473
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1473
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1474
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1474
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1475
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1475
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1476
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1476
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1477
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1477
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1480
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1480
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1481
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1481
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1482
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1482
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1483
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1483
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1484
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1484
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1485
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1485
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1486
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1486
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1488
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1488
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1489
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1489
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1491
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1491
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1492
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1492
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1493
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1493
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1509
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1510
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1511
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1513
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1514
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1515
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1516
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1517
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,1520
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,1542
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,1542
0,286,,FDA.gov,http://www.fda.gov/,1543
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,1544
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,1545
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1576
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1577
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1578
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1579
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1580
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1581
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1582
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1583
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1584
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1585
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1586
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1587
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1588
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1589
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1590
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1591
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1592
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1593
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1594
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1595
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1596
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1597
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1598
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1599
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1600
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1601
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1602
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1603
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1604
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1605
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1606
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1607
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1608
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1609
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1610
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1611
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1612
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1613
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1614
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1615
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1616
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1617
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1618
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1619
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1620
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1621
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1622
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1623
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1624
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1625
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1626
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1627
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1628
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1629
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1630
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1631
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1632
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1633
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1634
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1635
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1636
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1637
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1638
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1639
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1640
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1641
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1642
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1643
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1644
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1645
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1646
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1647
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1661
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1662
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1663
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1664
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1665
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1666
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1667
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1668
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1669
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1678
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1679
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1680
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1681
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1682
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1683
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1684
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1685
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1686
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1687
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1688
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1689
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1690
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1691
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1692
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1693
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1694
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1695
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1696
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1697
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1698
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1699
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1700
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1701
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1702
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1703
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1704
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1705
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1706
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1707
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1708
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1709
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1710
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1711
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1712
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1713
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1722
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1723
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,1724
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1725
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1726
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1727
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1728
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,1729
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,1730
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1868
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1869
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1870
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1871
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1872
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1873
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1874
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1875
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1876
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1877
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1878
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1879
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1880
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1881
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1882
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1883
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1884
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1885
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1886
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1887
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1888
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1889
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1890
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1891
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1892
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1893
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,1894
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1895
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1895
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1896
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1896
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1897
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1897
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1898
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1898
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1899
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1899
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1900
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1900
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1901
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1901
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1902
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1902
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1903
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1903
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1904
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1904
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1905
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1905
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1906
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1906
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1907
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1907
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1908
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1908
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1909
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1909
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1910
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1910
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1911
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1911
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1912
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1912
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1913
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1913
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1914
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1914
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1915
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1915
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1916
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1916
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1917
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1917
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1918
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1918
0,2241,24202394,Unraveling the therapeutic potential of the Hedgehog pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24202394,1920
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1921
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1921
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1922
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1922
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1923
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1923
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1924
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1924
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1926
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1926
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1928
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1928
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1929
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1929
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1930
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1930
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,1931
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,1932
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1938
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1939
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1940
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1941
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1942
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1943
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1944
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1945
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1946
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1947
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1948
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1949
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1950
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1951
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1952
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1953
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1954
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1955
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1956
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1957
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1958
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1959
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1960
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1961
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1962
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1963
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1964
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1965
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1966
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1967
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1968
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1969
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1970
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1971
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1972
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1973
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1974
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1975
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1976
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1977
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1978
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,1979
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1980
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1980
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1981
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1981
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1982
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1982
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1983
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1983
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1984
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1984
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,1985
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,1985
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,1986
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,1987
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,1992
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,1992
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,1993
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,1993
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,1998
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,1998
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,1999
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,1999
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2000
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2000
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2001
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2001
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2002
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2003
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2004
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2005
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2040
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,2040
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,2040
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,2041
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,2041
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,2042
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,2042
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2153
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2154
0,222,21639808.0,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,2188
1,286,,FDA.gov,http://www.fda.gov/,2188
2,467,22608338.0,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,2188
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2189
0,286,,FDA.gov,http://www.fda.gov/,2190
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2190
0,286,,FDA.gov,http://www.fda.gov/,2191
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2191
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2192
0,222,21639808.0,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,2193
1,286,,FDA.gov,http://www.fda.gov/,2193
2,467,22608338.0,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,2193
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2194
0,286,,FDA.gov,http://www.fda.gov/,2195
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2195
0,286,,FDA.gov,http://www.fda.gov/,2196
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2196
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2197
0,222,21639808.0,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,2198
1,286,,FDA.gov,http://www.fda.gov/,2198
2,467,22608338.0,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,2198
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2199
0,286,,FDA.gov,http://www.fda.gov/,2200
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2200
0,286,,FDA.gov,http://www.fda.gov/,2201
1,468,22663011.0,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,2201
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,2202
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2218
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2219
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2220
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2220
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2221
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2221
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2229
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2230
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2231
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2232
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2233
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2234
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2235
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2236
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2237
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2238
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2239
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2240
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2241
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2242
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2245
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2245
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,2246
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,2246
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2247
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2248
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2249
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2250
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2251
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2252
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2253
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2254
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2255
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2256
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2257
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2258
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2259
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2260
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2261
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2262
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2263
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2264
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2265
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2266
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2267
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2272
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2273
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2274
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2275
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2276
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2277
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2278
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2279
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2280
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2281
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2282
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2283
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2284
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2285
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2286
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2287
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2288
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2289
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2290
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2291
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2292
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2293
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2294
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2295
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,2308
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,2308
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,2308
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,2309
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2310
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2311
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2312
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2313
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2314
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2315
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2316
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,2317
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,2317
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,2317
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,2318
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,2318
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,2318
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,2319
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,2319
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,2319
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2320
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2321
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,2322
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,2323
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2356
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2357
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2358
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2359
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2360
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2361
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2362
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2363
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2364
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2365
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2366
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2367
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2368
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2369
0,2348,25559287,Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25559287,2548
0,973,24141978,A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24141978,2549
1,2349,23828214,Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/23828214,2549
2,2350,22897982,EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22897982,2549
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,2550
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,2851
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,2852
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,2861
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,2861
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2885
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2886
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2887
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2888
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2889
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2890
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2891
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2892
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2893
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2894
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2895
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2896
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2897
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,2898
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3009
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3010
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3011
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3012
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3013
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3014
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3015
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3016
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3017
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3018
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3019
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3020
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3021
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3022
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3023
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3024
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3025
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3026
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3027
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3028
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3029
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3030
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3031
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3032
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3033
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3034
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3035
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3036
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3037
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3038
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3039
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3040
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3041
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3042
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3043
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3044
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3045
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3046
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3047
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3048
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3049
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3050
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3051
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3052
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3053
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3054
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3055
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3056
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3057
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3058
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3059
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3060
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3061
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3062
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3063
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3064
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3065
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3066
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3067
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3068
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3069
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3070
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3071
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3072
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3073
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3074
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3075
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3076
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3077
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3078
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3079
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3080
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3081
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3082
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3083
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3084
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3189
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3190
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3328
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3329
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3382
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3383
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3390
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3391
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3392
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3393
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3394
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3395
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3396
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3397
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3398
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3399
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3403
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,3408
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,3408
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,3408
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3409
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3410
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3411
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3412
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3413
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3414
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3415
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3416
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3417
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3418
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3419
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3420
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3421
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3422
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3423
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3424
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3425
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3426
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3427
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3428
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3429
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3430
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3431
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3432
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3433
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,3434
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3435
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3436
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3437
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3438
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3439
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3440
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3441
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3442
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3443
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3446
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,3447
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3448
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3449
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,3450
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3451
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,3452
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3453
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3455
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,3482
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,3482
0,286,,FDA.gov,http://www.fda.gov/,3483
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,3484
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,3485
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3489
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3490
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3491
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3492
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3493
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3494
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3495
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3496
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,3497
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,3498
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3499
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,3500
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,3501
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,3577
0,287,,(NCI Drug Dictionary),http://www.cancer.gov/drugdictionary,3720
0,1125,24894453,Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/24894453,3727
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,3896
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,3897
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3899
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3899
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3899
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3900
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3900
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3900
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3901
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3901
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3901
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3902
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3902
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3902
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3903
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3903
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3903
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,3904
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,3904
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,3904
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,3905
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,3905
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,3906
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,3907
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,3908
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,3909
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,3910
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,3911
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,3912
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,3913
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,3914
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,3915
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,3915
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,3916
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,3916
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,3917
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,3917
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,3996
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,3996
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,3996
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,3997
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,3997
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,3997
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,3998
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,3998
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,3998
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,3999
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,3999
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,3999
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4000
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4000
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4000
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4001
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4001
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4001
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4002
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4002
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4002
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4003
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4003
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4003
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4004
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4004
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4004
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4005
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4005
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4005
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4006
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4006
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4006
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4007
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4007
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4007
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4015
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4016
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4016
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4017
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4018
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4018
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4019
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4020
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4020
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4022
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4023
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4023
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4024
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4025
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4025
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4026
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4027
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4027
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4028
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4029
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4029
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4030
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4031
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4031
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4036
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4036
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4037
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4037
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4038
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4038
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4039
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4039
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4040
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4040
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4041
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4041
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4042
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4042
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4043
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4043
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4044
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4044
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4045
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4045
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4056
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4056
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4075
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4075
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4076
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4076
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4077
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4077
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4078
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4078
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4079
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4079
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4080
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4080
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4081
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4081
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4082
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4082
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4087
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4088
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4089
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4090
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4091
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4092
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4093
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4094
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4095
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4096
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4097
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4098
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4101
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4102
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4103
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4104
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4105
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4106
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4107
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4108
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4111
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4112
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4113
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4113
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4114
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4115
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4116
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4117
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4118
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4119
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4120
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4121
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4122
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4123
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4124
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4125
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4126
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4127
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4128
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4129
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4130
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4131
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4132
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4133
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4134
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4135
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4136
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4137
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4138
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4139
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4140
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4141
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4142
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4143
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4144
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4145
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4146
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4146
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4147
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4148
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4153
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4154
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4155
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4156
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4157
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4158
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4159
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4160
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4161
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4162
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4163
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4164
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4165
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4166
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4167
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4168
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4169
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4170
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4171
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4172
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4173
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4174
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4175
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4176
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4177
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4178
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4179
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4180
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4181
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4182
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4183
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4184
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4185
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4186
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4187
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4188
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4189
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4190
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4191
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4192
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4193
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4194
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4195
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4196
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4197
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4198
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4199
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4200
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4201
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4202
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4203
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4204
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4205
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4206
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4207
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4208
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4209
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4210
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4211
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4212
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4213
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4214
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4215
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4216
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4217
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4218
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4219
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4220
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4221
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4222
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4222
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4222
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4223
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4223
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4231
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4231
0,2627,24959084,The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24959084,4232
0,2627,24959084,The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24959084,4233
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,4234
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4255
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4256
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4257
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4258
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4259
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4260
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4261
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4262
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4263
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4264
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4265
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4266
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4267
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4268
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4269
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4270
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4271
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,4272
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4289
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4289
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4290
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4290
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4291
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4291
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4292
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4292
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4293
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4293
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4294
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4294
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4295
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4295
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4296
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4296
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4297
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4297
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4298
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4298
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4299
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4299
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4300
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4300
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4301
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4301
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,4302
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,4302
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4303
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4304
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4305
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4312
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4313
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4314
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4315
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4316
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4317
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4318
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4319
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4320
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4321
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4322
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4323
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4324
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4325
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4326
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4327
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4328
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4329
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4330
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4331
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4332
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4333
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,4334
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,4335
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4336
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4337
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4338
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4339
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4340
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4341
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4342
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,4343
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,4343
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,4343
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4344
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4345
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4346
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4347
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4348
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4349
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,4350
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,4350
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4353
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4358
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4359
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4360
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4361
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4362
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4372
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4373
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4374
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4375
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4376
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4377
0,537,24893891,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24893891,4379
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,4380
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,4380
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4381
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4382
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4383
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4384
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4385
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4386
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4387
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4388
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,4389
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,4389
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4397
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4398
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4399
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4400
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,4434
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,4435
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,4436
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,4437
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,4438
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4455
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4456
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4457
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4458
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4458
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4458
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4459
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4460
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4460
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4460
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4461
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4462
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4462
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4462
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4463
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4464
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4464
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4464
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4465
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4466
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4466
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4466
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4467
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4468
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4468
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4468
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4469
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4470
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4470
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4470
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4471
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4472
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4472
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4472
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4473
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4474
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4474
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4474
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4477
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4478
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4478
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4478
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4479
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4480
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4480
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4480
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4481
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4482
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4482
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4482
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4483
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4484
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4484
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4484
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4485
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4486
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4486
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4486
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4487
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4488
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4488
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4488
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4489
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4490
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4490
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4490
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4491
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4492
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4492
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4492
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4493
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4494
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4494
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4494
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4495
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4496
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4496
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4496
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4497
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4498
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4498
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4498
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,4499
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,4500
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,4500
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,4500
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4524
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4524
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4524
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4525
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4525
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4525
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,4526
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,4526
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,4526
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4558
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4559
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4560
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4561
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4562
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4563
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4564
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4565
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4566
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4567
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4568
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4569
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4570
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4571
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4572
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4573
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4574
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4575
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4576
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4578
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4579
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4580
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4581
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4582
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,4583
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4586
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4586
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4587
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4587
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4588
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4588
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4589
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4589
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4590
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4590
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4591
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4591
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4592
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4592
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4593
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4593
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,4594
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,4594
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4595
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4596
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4597
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4609
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4609
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4610
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4610
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4611
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4611
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4612
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4612
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4613
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4613
0,286,,FDA.gov,http://www.fda.gov/,4614
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4615
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4616
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4617
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4618
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4618
0,286,,FDA.gov,http://www.fda.gov/,4619
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4620
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4621
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4622
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4623
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4623
0,286,,FDA.gov,http://www.fda.gov/,4624
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4625
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4626
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4627
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4628
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4628
0,286,,FDA.gov,http://www.fda.gov/,4629
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4630
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4631
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4632
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4633
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4633
0,286,,FDA.gov,http://www.fda.gov/,4634
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4635
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4636
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4637
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4638
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4638
0,286,,FDA.gov,http://www.fda.gov/,4639
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4640
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4641
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4642
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4643
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4643
0,286,,FDA.gov,http://www.fda.gov/,4644
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4645
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4646
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4647
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4648
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4648
0,286,,FDA.gov,http://www.fda.gov/,4649
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4650
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4651
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4652
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4653
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4653
0,286,,FDA.gov,http://www.fda.gov/,4654
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4655
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4656
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4657
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4658
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4658
0,286,,FDA.gov,http://www.fda.gov/,4659
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4660
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4661
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4662
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4673
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4673
0,286,,FDA.gov,http://www.fda.gov/,4674
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4675
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4676
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4677
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4678
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4678
0,286,,FDA.gov,http://www.fda.gov/,4679
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4680
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4681
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4682
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4683
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4683
0,286,,FDA.gov,http://www.fda.gov/,4684
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4685
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4686
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4687
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4688
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4688
0,286,,FDA.gov,http://www.fda.gov/,4689
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4690
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4691
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4692
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4693
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4693
0,286,,FDA.gov,http://www.fda.gov/,4694
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4695
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4696
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4697
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4698
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4698
0,286,,FDA.gov,http://www.fda.gov/,4699
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4700
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4701
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4702
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4703
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4703
0,286,,FDA.gov,http://www.fda.gov/,4704
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4705
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4706
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4707
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4708
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4708
0,286,,FDA.gov,http://www.fda.gov/,4709
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4710
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4711
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4712
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4713
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4713
0,286,,FDA.gov,http://www.fda.gov/,4714
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4715
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4716
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4717
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4718
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4718
0,286,,FDA.gov,http://www.fda.gov/,4719
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4720
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4721
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4722
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4723
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4723
0,286,,FDA.gov,http://www.fda.gov/,4724
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4725
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4726
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4727
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4733
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4733
0,286,,FDA.gov,http://www.fda.gov/,4734
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4735
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4736
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4737
0,593,22761403,"Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.",http://www.ncbi.nlm.nih.gov/pubmed/22761403,4738
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4739
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4739
0,286,,FDA.gov,http://www.fda.gov/,4740
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4741
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4742
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4743
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4744
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4744
0,286,,FDA.gov,http://www.fda.gov/,4745
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4746
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4747
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4748
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4749
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4749
0,286,,FDA.gov,http://www.fda.gov/,4750
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4751
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4752
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4753
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4754
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4754
0,286,,FDA.gov,http://www.fda.gov/,4755
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4756
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4757
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4758
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4759
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4759
0,286,,FDA.gov,http://www.fda.gov/,4760
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4761
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4762
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4763
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4764
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4764
0,286,,FDA.gov,http://www.fda.gov/,4765
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4766
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4767
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4768
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4769
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4769
0,286,,FDA.gov,http://www.fda.gov/,4770
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4771
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4772
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4773
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4774
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4774
0,286,,FDA.gov,http://www.fda.gov/,4775
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4776
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4777
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4778
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4779
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4779
0,286,,FDA.gov,http://www.fda.gov/,4780
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4781
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4782
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4783
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4784
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4784
0,286,,FDA.gov,http://www.fda.gov/,4785
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4786
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4787
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4788
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4789
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4789
0,286,,FDA.gov,http://www.fda.gov/,4790
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4791
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4792
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4793
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,4794
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4794
0,286,,FDA.gov,http://www.fda.gov/,4795
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4796
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,4797
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,4798
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4811
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4811
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4812
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4812
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4813
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4813
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4814
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4814
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4815
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4815
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,4816
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,4816
0,537,24893891,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24893891,4856
0,537,24893891,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24893891,4857
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4871
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,4872
0,2810,25853747,Ibrutinib in previously treated Waldenström's macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/25853747,4938
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5002
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5002
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5002
0,1168,24822169,DNA methyltransferases: a novel target for prevention and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24822169,5008
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5011
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5012
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5025
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5025
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5025
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5026
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5026
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5026
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5027
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5027
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5027
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5028
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5028
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5028
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5029
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5029
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5029
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5030
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5030
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5030
0,1168,24822169,DNA methyltransferases: a novel target for prevention and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24822169,5032
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5033
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5033
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5034
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5034
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5035
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5036
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5037
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5037
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5037
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5045
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5045
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5045
0,1168,24822169,DNA methyltransferases: a novel target for prevention and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24822169,5050
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5147
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5148
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5149
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5150
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5151
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5152
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5153
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5154
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5155
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5156
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5157
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5158
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5159
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5160
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5161
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5162
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5163
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5164
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5174
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5175
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5176
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5177
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5178
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5179
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5180
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5181
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5182
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5183
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5184
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5185
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5186
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5187
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5188
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5189
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5190
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5191
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5192
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5193
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5194
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5195
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5196
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5197
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5198
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5199
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5200
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5201
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5202
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5203
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5204
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5205
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5206
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5207
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5208
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5209
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5263
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5264
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5265
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5265
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5266
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5266
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5267
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5268
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5268
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5269
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5269
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5270
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5271
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5271
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5272
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5272
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5273
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5274
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5274
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5275
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5275
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5276
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5277
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5277
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5278
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5278
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,5279
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5280
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,5280
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,5281
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,5281
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5314
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5315
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5333
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5334
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5335
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5336
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5337
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5338
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5339
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5340
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5341
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5342
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5343
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,5344
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5345
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5346
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5347
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,5348
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5351
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5352
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5353
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5354
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5355
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5356
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5357
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5358
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5359
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5360
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5361
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5362
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5363
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5364
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5365
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,5366
0,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,5456
1,3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549,5456
0,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,5457
1,3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549,5457
0,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,5458
1,3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549,5458
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5486
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5486
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5486
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5487
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5487
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5487
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,5488
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,5488
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,5488
0,3125,,"Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation",http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short,5837
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,5931
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,5931
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5934
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5935
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5936
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5937
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5938
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5939
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,5959
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,5960
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,5961
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,5961
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,5962
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,5962
0,839,23748344,AKT is a therapeutic target in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23748344,5963
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5964
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5965
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5966
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,5967
0,3211,26078430,Targeting FGFR Signaling in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26078430,5969
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,5970
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,5971
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,5971
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,5977
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,5978
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,5984
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,5985
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,6008
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,6009
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,6011
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6014
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6015
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6015
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6016
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6016
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6023
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6024
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6024
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6025
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6025
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6029
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6030
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6030
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6031
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6031
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6042
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6043
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6043
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6044
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6044
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6045
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6046
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6046
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6047
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6047
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6051
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6052
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6052
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6053
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6053
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6060
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6061
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6061
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6062
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6062
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6063
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6064
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6064
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6065
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6065
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6069
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6070
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6070
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6071
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6071
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6072
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6073
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6073
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6074
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6074
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6075
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6076
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6076
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6077
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6077
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6078
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6079
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6079
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6080
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6080
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6081
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6082
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6082
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6083
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6083
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6084
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6085
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6085
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6086
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6086
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6096
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6097
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6097
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6098
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6098
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6102
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6103
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6103
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6104
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6104
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,6105
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6106
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,6106
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,6107
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,6107
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,6114
0,2241,24202394,Unraveling the therapeutic potential of the Hedgehog pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24202394,6118
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,6119
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,6120
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,6121
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,6122
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6123
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6124
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6125
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6126
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6127
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6128
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6129
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6131
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6132
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,6133
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,6138
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,6138
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,6139
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,6139
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,6140
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,6140
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,6141
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,6141
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,6142
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,6143
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,6144
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,6145
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,6146
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,6147
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,6148
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,6149
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,6150
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,6207
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,6207
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,6208
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,6208
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,6326
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,6326
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6344
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6344
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6345
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6345
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6346
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6346
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6347
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6347
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6348
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6348
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6349
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6349
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6350
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6350
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6351
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6351
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6352
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6352
0,3386,25806224,Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).,http://www.ncbi.nlm.nih.gov/pubmed/25806224,6353
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,6356
1,3392,25294908,Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25294908,6356
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,6357
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,6357
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,6412
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,6412
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,6413
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,6413
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,6422
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,6423
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,6423
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,6423
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,6424
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,6425
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,6425
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,6425
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,6426
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,6427
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,6427
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,6427
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,6428
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,6429
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,6430
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,6430
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,6430
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,6431
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6431
0,286,,FDA.gov,http://www.fda.gov/,6432
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6433
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6434
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,6435
0,3598,21474455,Targeting oncogenic ALK: a promising strategy for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/21474455,6436
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,6437
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,6438
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,6439
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,6440
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,6440
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,6441
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,6441
0,1846,24063894,Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.,http://www.ncbi.nlm.nih.gov/pubmed/24063894,6460
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,6482
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,6482
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6500
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6500
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6502
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6502
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6503
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6503
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6504
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6504
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6505
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6505
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6506
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6506
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6507
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6507
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6510
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6510
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6511
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6511
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6512
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6512
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6513
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6513
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6514
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6514
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6515
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6515
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6516
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6516
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6517
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6517
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6518
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6518
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6519
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6519
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6522
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6522
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6523
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6523
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6524
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6524
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6525
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6525
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6526
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6526
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6527
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6527
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6528
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6528
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6529
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6529
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6530
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6530
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6531
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6531
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6532
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6532
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6533
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6533
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6534
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6534
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6535
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6535
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6536
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6536
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6537
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6537
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6538
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6538
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6539
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6539
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6540
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6540
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6541
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6541
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6542
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6542
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6543
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6543
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6544
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6544
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6545
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6545
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6548
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6548
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6549
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6549
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6550
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6550
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6551
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6551
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6552
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6552
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6553
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6553
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6554
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6554
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6555
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6555
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6556
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6556
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6557
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6557
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6560
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6560
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6561
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6561
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6562
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6562
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6563
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6563
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6564
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6564
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6565
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6565
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6566
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6566
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6567
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6567
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6568
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6568
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6569
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6569
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6570
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6570
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6571
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6571
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6572
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6572
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6573
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6573
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6576
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6576
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6577
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6577
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6586
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6586
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6587
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6587
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6590
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6590
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6591
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6591
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6592
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6592
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6593
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6593
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6594
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6594
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6595
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6595
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6596
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6596
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6597
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6597
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6598
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6598
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6599
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6599
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6600
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6600
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6601
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6601
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6602
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6602
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6603
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6603
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6608
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6608
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6609
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6609
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6610
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6610
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6611
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6611
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6612
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6612
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6613
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6613
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6618
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6618
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6619
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6619
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6622
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6622
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6623
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6623
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6624
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6624
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6625
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6625
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6626
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6626
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6627
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6627
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6630
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6630
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6631
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6631
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6632
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6632
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6633
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6633
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6634
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6634
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6635
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6635
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6636
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6636
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6637
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6637
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6638
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6638
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6639
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6639
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6640
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6640
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6641
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6641
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6646
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6646
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6647
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6647
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6648
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6648
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6649
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6649
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6650
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6650
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6651
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6651
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6652
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6652
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6653
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6653
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6654
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6654
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6655
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6655
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6656
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6656
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6657
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6657
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6658
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6658
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6659
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6659
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6660
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6660
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6661
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6661
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6662
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6662
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6663
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6663
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6664
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,6664
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6665
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6665
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6666
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6666
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6715
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6715
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6716
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6716
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6717
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6717
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6718
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6718
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6719
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6719
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6720
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6720
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6721
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6721
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6722
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6722
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6723
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6723
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6724
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6724
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6725
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6725
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6726
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6726
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6727
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6727
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6728
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6728
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6729
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6729
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6730
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6730
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6731
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6731
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6732
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6732
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6736
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6736
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6737
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6737
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6738
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6738
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6739
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6739
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6740
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6740
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6741
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6741
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6742
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6742
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6743
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6743
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6744
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6744
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6745
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6745
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6746
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6746
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6747
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6747
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6748
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6748
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6749
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6749
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6750
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6750
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6751
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6751
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6752
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6752
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6753
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6753
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6757
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6757
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6758
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6758
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6762
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6762
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6763
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6763
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6764
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6764
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6765
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6765
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6766
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6766
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6767
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6767
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6768
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6768
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6769
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6769
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6770
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6770
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6771
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6771
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6772
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6772
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6773
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6773
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6774
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6774
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6775
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6775
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6776
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6776
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6777
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6777
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6778
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6778
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6779
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6779
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6780
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6780
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6781
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6781
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6788
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6788
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6789
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6789
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6790
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6790
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6791
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6791
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6792
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6792
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6793
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6793
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6794
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6794
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6795
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6795
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6796
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6796
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6797
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6797
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6798
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6798
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6799
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6799
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6802
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6802
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6803
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6803
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6806
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6806
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6807
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6807
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6808
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6808
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6809
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6809
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6812
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6812
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6813
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6813
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6816
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6816
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6817
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6817
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6818
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6818
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6819
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6819
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6824
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6824
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6825
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6825
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6832
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6832
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6833
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6833
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6909
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6909
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6909
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6910
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6910
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6910
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6911
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6911
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6911
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6912
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6912
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6912
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6913
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6913
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6913
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,6914
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,6914
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,6914
0,3183,21148487,ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21148487,6916
1,4250,16258068,The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16258068,6916
0,3695,25207766,Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25207766,6917
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6939
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6940
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6941
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6942
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6943
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6944
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6945
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6946
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,6947
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,6968
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,6968
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,6968
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,6969
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,6970
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,6970
0,3277,,Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC,http://cancerres.aacrjournals.org/content/74/19_Supplement/4766.abstract,6979
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,6984
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6984
0,286,,FDA.gov,http://www.fda.gov/,6985
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6986
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,6987
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,6988
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,6995
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,6995
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,6995
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6996
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6996
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6997
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6997
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,6998
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,6998
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,6999
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,6999
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7000
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7000
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7001
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7001
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7002
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7002
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7003
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7003
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7006
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7006
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7007
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7007
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7010
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7010
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7011
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7011
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7014
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7014
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7015
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7015
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7016
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7016
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7017
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7017
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7018
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7018
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7019
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7019
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7020
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7020
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7021
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7021
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7022
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7022
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7023
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7023
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7024
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7024
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7025
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7025
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7026
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7026
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7027
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7027
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7030
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7030
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7031
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7031
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7032
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7032
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7033
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7033
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7036
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7036
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7037
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7037
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7038
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7038
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7039
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7039
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7040
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7040
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7041
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7041
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7042
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7042
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7043
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7043
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7044
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7044
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7045
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7045
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,7047
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,7047
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,7048
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,7048
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,7049
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,7050
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,7051
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,7052
0,3822,18024392,"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.",http://www.ncbi.nlm.nih.gov/pubmed/18024392,7054
0,3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424,7055
0,3822,18024392,"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.",http://www.ncbi.nlm.nih.gov/pubmed/18024392,7056
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,7057
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,7058
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,7059
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,7059
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,7060
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,7060
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7061
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7062
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7063
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,7065
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7066
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,7066
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7067
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,7067
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,7068
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7069
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,7069
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7070
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,7070
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,7071
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7072
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,7072
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7073
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,7073
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,7074
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7075
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,7075
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7076
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,7076
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,7077
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7078
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,7078
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,7079
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,7079
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,7081
0,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,7082
1,1847,25568876,Clinical advances in the development of novel VEGFR2 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25568876,7082
0,3953,24325356,Somatic mutations of calreticulin in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24325356,7086
1,3954,24645956,JAK inhibitor in CALR-mutant myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/24645956,7086
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7098
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7099
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7101
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7102
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7103
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7104
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7105
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,7106
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7114
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7115
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7116
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7117
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7118
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7119
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7132
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7133
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7134
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7135
1,4003,26366092,Chronic neutrophilic leukemia: a clinical perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26366092,7135
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7136
1,4003,26366092,Chronic neutrophilic leukemia: a clinical perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26366092,7136
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7137
1,4003,26366092,Chronic neutrophilic leukemia: a clinical perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26366092,7137
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7159
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7160
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7161
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7162
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7163
0,286,,FDA.gov,http://www.fda.gov/,7164
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,7165
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7166
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,7167
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7167
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7168
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7169
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,7170
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7171
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,7172
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7172
0,286,,FDA.gov,http://www.fda.gov/,7173
0,286,,FDA.gov,http://www.fda.gov/,7174
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,7175
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7176
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,7177
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7177
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7178
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7179
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7180
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,7181
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7181
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,7182
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7183
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7184
0,286,,FDA.gov,http://www.fda.gov/,7185
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,7186
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7186
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,7187
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7188
0,286,,FDA.gov,http://www.fda.gov/,7189
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,7190
0,4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,7191
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7223
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7223
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7224
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7224
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,7226
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,7227
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,7227
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,7227
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7239
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7240
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7241
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7242
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7243
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7244
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7245
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7246
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7247
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7248
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7249
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7250
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7251
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7252
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7253
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7254
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7255
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7256
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7257
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7258
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7259
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7260
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7261
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7262
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7263
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7264
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7265
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7266
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7267
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7268
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7269
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7270
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7271
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7272
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7273
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7274
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,7280
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,7280
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7283
1,4003,26366092,Chronic neutrophilic leukemia: a clinical perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26366092,7283
0,3183,21148487,ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21148487,7313
1,4256,21804605,"A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.",http://www.ncbi.nlm.nih.gov/pubmed/21804605,7313
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7314
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7315
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7316
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7317
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7318
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7319
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7320
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7321
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7343
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7344
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7345
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7346
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7347
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7348
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7349
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7349
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7350
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7350
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7351
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7351
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7352
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7352
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7353
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7353
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7354
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7354
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7355
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7355
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7356
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7356
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7357
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7357
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7358
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7358
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,7359
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,7359
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7360
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7361
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7362
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7363
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7364
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7365
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7366
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7367
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7368
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7369
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7370
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7371
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7372
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7373
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7374
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7375
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7376
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7377
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7379
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7380
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7381
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7382
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7383
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7384
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7385
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7386
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,7387
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7388
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7389
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7390
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7391
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7392
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7393
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7394
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7395
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7396
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7397
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7398
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7399
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7401
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7402
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,7413
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,7413
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,7414
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,7414
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,7414
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,7417
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,7417
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,7418
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,7418
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,7419
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,7419
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,7420
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,7420
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7421
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7421
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7422
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7422
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7423
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7423
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7424
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7424
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7425
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7425
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7426
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7426
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7427
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7427
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7428
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7428
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7429
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7429
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7430
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7430
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,7431
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,7431
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7432
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,7432
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,7440
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,7441
0,3393,23298836,The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23298836,7443
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7444
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7445
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7446
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7447
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7448
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7449
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7450
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7451
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7452
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7453
0,1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830,7454
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7455
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7456
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7457
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7458
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7459
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7460
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7461
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7462
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7463
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7464
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7465
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7466
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7467
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7468
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7469
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7470
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7471
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7472
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7473
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7474
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7475
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7476
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7477
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7478
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7479
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7480
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7481
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7482
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7483
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7484
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7485
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7486
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7487
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7488
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7489
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7490
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7491
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7492
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7493
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7494
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7495
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7496
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7497
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7498
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7499
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7500
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7501
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7502
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7503
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7504
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7505
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7506
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7507
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7508
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7509
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7510
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7511
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7512
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7513
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7514
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7515
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7516
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7517
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7518
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7519
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7520
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7521
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7521
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7522
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7522
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7523
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7524
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7524
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7525
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7526
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7526
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7527
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7528
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7528
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7529
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7530
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7531
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7531
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7532
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7533
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7533
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7534
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7535
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7535
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7536
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7536
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7537
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7538
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7538
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7539
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7540
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7541
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7541
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7542
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7542
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7543
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7544
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7545
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7545
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7546
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7546
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7547
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7548
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7548
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7549
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7550
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7550
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7551
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7554
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7555
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7555
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7556
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7556
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7557
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7558
0,3211,26078430,Targeting FGFR Signaling in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26078430,7559
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7560
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,7560
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,7574
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,7575
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,7576
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,7577
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7578
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7578
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7579
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7579
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7581
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7582
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,7592
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7593
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7594
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7595
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7596
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,7597
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,7598
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7599
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7600
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7606
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7607
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7610
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7611
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7612
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7613
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7706
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7706
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7707
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7707
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7708
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7708
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7709
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7709
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7710
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7710
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7711
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7711
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,7712
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,7712
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7734
1,4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182,7734
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7735
1,4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182,7735
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7736
1,4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182,7736
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7737
1,4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182,7737
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7740
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,7743
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,7743
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,7743
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7763
1,4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182,7763
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,7816
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,7817
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,7818
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,7818
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,7819
0,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,7829
1,3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549,7829
0,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,7856
1,1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969,7856
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,7862
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,7863
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,7863
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7874
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7875
0,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,7876
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7882
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,7883
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,7891
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,7891
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,7891
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,7892
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,7892
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,7892
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7893
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7894
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7895
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7896
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7897
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,7898
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,7899
0,4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084,7900
0,2241,24202394,Unraveling the therapeutic potential of the Hedgehog pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24202394,7901
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,7902
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,7917
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,7917
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,7917
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7931
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7932
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7933
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7933
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7934
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7935
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7935
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7936
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7937
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7938
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7939
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7939
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7940
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7941
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7941
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7942
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7943
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7943
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7944
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7945
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7946
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7946
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7947
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7948
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7949
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7950
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7950
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7951
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7952
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7952
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7953
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7954
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7955
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7955
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7956
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7957
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7958
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7958
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7959
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7960
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7961
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7961
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7962
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7963
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7964
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7965
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7966
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7966
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7967
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7967
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7968
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7969
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7970
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7971
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7971
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7972
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7973
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7973
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7974
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7975
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7976
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7977
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7977
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7978
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7979
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7980
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7980
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7981
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7982
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7983
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7983
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7984
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7985
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7986
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7986
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7987
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7988
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7989
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7990
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7990
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7991
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7992
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7993
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7993
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7994
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7995
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7996
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7996
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,7997
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,7998
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,7998
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,7999
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8000
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8000
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8001
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8002
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8003
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8003
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8004
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8005
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8006
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8007
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8007
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8008
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8009
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8010
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8011
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8011
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8012
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8012
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8013
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8014
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8015
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8015
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8016
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8017
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8018
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8019
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8020
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8020
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8021
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8022
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8022
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8023
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8024
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8025
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8026
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8026
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8027
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8028
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8029
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8029
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8030
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8030
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8031
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8032
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8033
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8033
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8034
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8035
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8036
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8037
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8038
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8038
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8039
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8040
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8041
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8041
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8042
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8042
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8043
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8044
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8045
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8046
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8046
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8047
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8048
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8048
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8049
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8050
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8051
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8052
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8053
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8053
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8054
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8055
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8055
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8056
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8057
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8058
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8059
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8059
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8060
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8061
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8062
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8062
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8063
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8064
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8065
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8065
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8066
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8067
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8067
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8068
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8069
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8070
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8070
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8071
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8072
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8072
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8073
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8074
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8075
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8075
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8076
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8077
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8078
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8079
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8080
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8080
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8081
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8081
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8082
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8083
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8084
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8084
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8085
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8086
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8087
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8088
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8089
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8089
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8090
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8091
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8092
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8092
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,8094
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8095
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8096
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,8096
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,8097
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,8098
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,8099
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,8100
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8150
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8151
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8152
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8153
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8154
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8155
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8156
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8157
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8158
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8159
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8160
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8161
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8162
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8163
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8164
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8165
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8166
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8167
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8168
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8169
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8170
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8171
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8172
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8173
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8174
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8175
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8176
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8252
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8255
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8256
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8257
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8258
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8259
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8260
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8261
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8262
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8264
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,8264
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,8265
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,8265
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8266
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8267
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8268
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8269
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8270
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,8271
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,8272
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,8272
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,8272
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,8273
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,8273
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,8273
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,8274
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,8275
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,8276
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,8276
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,8276
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,8277
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,8278
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,8278
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,8278
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8279
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8280
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,8280
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8281
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,8281
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,8282
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8283
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8284
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8285
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8286
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8287
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8288
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8289
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8290
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,8291
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8292
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8293
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,8294
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8295
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8296
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8297
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8298
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8299
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8300
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8310
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8310
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8311
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8311
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8312
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8312
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8313
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8313
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8314
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8314
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8315
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8315
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,8316
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,8316
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8327
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8327
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8328
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8328
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8329
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8351
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8351
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8352
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8353
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8353
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8354
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8354
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8355
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8356
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8356
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8357
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8357
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8358
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8358
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8359
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8360
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8360
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8361
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8362
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8362
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8363
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,8363
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,8364
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,8364
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,8365
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8374
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8375
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,8376
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8377
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8378
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8379
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8380
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,8381
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,8382
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8388
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8388
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8389
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8389
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8390
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8391
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8392
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8392
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8393
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8393
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8394
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8395
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8395
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8396
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8397
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8397
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8398
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8399
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8399
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8400
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8401
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8401
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8402
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8403
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8404
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8404
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8405
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8406
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8406
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8407
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8407
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8408
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8409
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8409
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8410
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8411
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8412
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8412
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8413
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8414
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8414
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8415
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8415
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8416
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8417
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8418
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8418
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8419
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8419
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8420
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8421
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8421
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8422
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8423
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8423
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8424
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8425
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8425
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8426
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8427
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8427
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8428
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8429
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8429
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8430
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8431
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8431
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8432
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8433
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8433
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8434
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8435
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8436
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8436
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8437
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8437
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8438
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8439
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8440
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8440
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8441
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8442
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8442
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8443
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8444
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8444
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8445
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8446
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8446
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8447
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8447
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8448
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8449
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8450
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8450
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8451
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8452
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8452
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8453
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8453
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8454
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8455
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8456
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8456
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8457
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8458
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8458
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8459
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8459
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8460
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8461
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8462
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8462
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8463
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8463
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8464
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8465
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8465
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8466
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8467
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8468
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8468
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8469
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8470
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8470
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8471
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8471
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8472
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,8474
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,8474
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,8475
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8501
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8502
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8503
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8504
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8505
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8506
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8507
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8508
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,8509
0,3953,24325356,Somatic mutations of calreticulin in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24325356,8515
1,3954,24645956,JAK inhibitor in CALR-mutant myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/24645956,8515
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8516
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8517
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8518
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8519
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8520
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,8521
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8526
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8526
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8527
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8527
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8528
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8528
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8529
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8529
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8530
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8530
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8531
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8531
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8532
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8533
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8534
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8535
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8536
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8537
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8538
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8539
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8540
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8541
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8542
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8543
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8544
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8545
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8547
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8576
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8578
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8580
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8581
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8581
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8582
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8582
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8618
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8619
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8619
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8620
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8621
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8621
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8622
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8622
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8623
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8624
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8624
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8625
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8626
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8626
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8627
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8628
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8629
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8629
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8630
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8630
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8631
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8632
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8633
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8633
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8634
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8634
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8635
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8636
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8636
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8637
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8638
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8639
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8639
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8640
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8640
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8641
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8642
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8642
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8643
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8644
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8645
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8645
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8646
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8646
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8647
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8647
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8648
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8649
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8650
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8651
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8652
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8652
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8653
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8653
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8654
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8654
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8655
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8655
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8656
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8657
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8658
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8658
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8659
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8660
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8661
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8661
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8662
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8662
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8663
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8664
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8664
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8665
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8666
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8666
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8667
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8668
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8668
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8669
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8670
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8670
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8671
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8672
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8672
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8673
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8674
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8674
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8675
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8676
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8677
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8677
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8678
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8678
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8679
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8680
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8681
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8681
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8682
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8683
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8683
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8684
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8685
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8685
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8686
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8686
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8687
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8688
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8689
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8689
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8690
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8690
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8691
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8691
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8692
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8693
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8694
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8694
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8695
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8696
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8697
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8697
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8698
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8699
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8700
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8700
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8701
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8701
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8702
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8702
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8703
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8704
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8705
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8705
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8706
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8706
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8707
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8708
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8709
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8709
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8710
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8711
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8712
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8712
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8713
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8713
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8714
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8714
0,836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402,8715
1,837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492,8715
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8716
0,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,8717
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8718
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8719
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,8744
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,8745
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,8745
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,8746
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,8746
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,8747
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,8747
0,2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173,8748
1,2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602,8748
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8759
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8760
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8760
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8761
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8761
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8762
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8762
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8763
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8763
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8764
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8764
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8765
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8765
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8766
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8766
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8767
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8767
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8768
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8768
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8769
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8769
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8770
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8770
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8771
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8771
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8772
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8772
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8773
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8773
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8774
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8774
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8775
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8775
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8796
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8797
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8798
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8799
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8800
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8801
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8802
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,8803
0,5485,23138183,Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.,http://www.ncbi.nlm.nih.gov/pubmed/23138183,8838
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8839
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8840
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8841
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8842
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8843
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8844
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8845
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8846
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8847
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8848
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8849
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8850
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8851
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8852
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8853
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8854
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8855
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8856
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8857
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8858
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8859
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8860
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8861
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8862
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8863
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8864
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8865
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8866
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8867
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8868
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8869
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8870
0,2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515,8871
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8872
0,5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868,8873
0,2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237,8874
0,2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003,8875
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,8881
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,8882
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,8883
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,8883
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8884
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,8885
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8954
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8954
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,8957
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,8958
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8959
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8959
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8960
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8960
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8961
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8961
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8962
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8962
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8963
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8963
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8964
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8964
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8965
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8965
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8966
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8966
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8967
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8967
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,8971
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,8971
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,8972
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,8973
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,8973
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,8973
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8974
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8974
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8975
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8975
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8991
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8991
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,8992
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,8992
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,9073
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,9073
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9076
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9077
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9078
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9079
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,9086
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,9087
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,9088
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,9089
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9090
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9091
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9092
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9093
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9094
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9095
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9096
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9097
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9098
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9099
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9100
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9101
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9102
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9103
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9104
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9105
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9106
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9107
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9108
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9109
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9110
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9111
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9112
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9113
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9114
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9115
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9116
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9117
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9118
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9119
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9120
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,9121
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9282
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9283
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9284
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9285
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9286
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9287
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9288
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9289
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9290
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9291
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9292
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9293
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9294
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9295
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9296
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9297
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9298
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9299
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9300
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9301
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9302
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9303
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9304
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9305
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9306
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9307
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9308
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9309
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9310
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9311
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9312
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9313
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9314
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9315
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9316
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,9317
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,9349
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,9349
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9350
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9350
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9351
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9351
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,9363
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,9363
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9364
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9364
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9365
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9365
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9366
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9366
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9367
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9367
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,9368
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,9368
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,9369
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,9369
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9370
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9370
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9371
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9371
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,9372
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,9372
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9373
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9373
0,286,,FDA.gov,http://www.fda.gov/,9374
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9375
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9376
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9377
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9378
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9378
0,286,,FDA.gov,http://www.fda.gov/,9379
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9380
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9381
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9382
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9383
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9383
0,286,,FDA.gov,http://www.fda.gov/,9384
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9385
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9386
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9387
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9408
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9408
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,9409
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,9409
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9416
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9417
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9418
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9419
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9420
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9421
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9422
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9423
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,9424
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9425
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9426
0,445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291,9427
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9428
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9429
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9430
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9431
0,1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957,9432
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,9433
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9434
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9434
0,286,,FDA.gov,http://www.fda.gov/,9435
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9436
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9437
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9438
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,9439
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9440
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9440
0,286,,FDA.gov,http://www.fda.gov/,9441
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9442
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9443
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9444
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9445
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9445
0,286,,FDA.gov,http://www.fda.gov/,9446
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9447
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9448
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9449
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,9458
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,9458
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,9459
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,9459
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,9468
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,9468
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9469
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9470
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9471
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9472
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9473
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9474
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9475
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9476
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9477
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9478
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9479
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9480
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9481
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9482
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9483
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9484
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9485
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9486
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9487
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9488
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9489
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9490
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9491
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9492
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9493
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9494
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9495
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9496
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9497
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9498
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9498
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9498
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9499
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9500
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9501
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9502
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9503
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9504
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9505
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9506
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9507
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9508
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9509
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9510
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9511
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9512
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9513
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9514
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9515
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9516
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9517
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9518
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9519
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9520
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9521
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9522
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9523
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9524
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9525
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9526
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9527
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9528
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9529
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9530
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9531
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9532
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9533
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9534
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9535
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9536
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9536
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9536
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9537
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9538
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9538
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9538
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9539
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9539
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9540
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9540
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9541
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9541
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9542
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9542
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9543
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9543
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9544
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9544
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9545
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9545
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9546
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9546
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9547
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9547
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9548
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9548
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9549
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9549
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,9550
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,9550
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,9550
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,9551
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,9551
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,9551
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,9552
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,9552
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,9552
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,9553
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,9553
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,9553
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9554
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9555
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9555
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9555
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9556
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9557
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9557
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9557
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9558
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9559
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9559
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9559
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9563
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9563
0,4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,9564
1,4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780,9564
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9565
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9566
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9567
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9568
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9569
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9570
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9571
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9572
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9573
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9574
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9575
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9576
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9577
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9578
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9579
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9580
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9581
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9582
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9583
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9584
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9585
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9586
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9587
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9588
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9589
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9590
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9591
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9592
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9593
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9594
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9595
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9596
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9597
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9598
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9599
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9600
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9601
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9602
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9603
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9604
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9605
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9606
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9607
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9608
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9611
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9612
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9613
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9614
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9615
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9616
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9617
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9618
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9619
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9620
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9621
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9622
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9623
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9624
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9625
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9626
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9627
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9628
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9629
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9630
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,9631
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9631
0,286,,FDA.gov,http://www.fda.gov/,9632
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9633
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,9634
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,9635
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9636
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9637
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9638
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9639
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9640
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9641
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9642
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9643
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9644
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9645
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9646
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9647
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9648
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9649
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9650
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9651
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9652
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9653
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9654
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9655
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9656
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9657
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9658
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9659
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9660
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9661
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9662
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9663
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9664
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9665
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9666
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9667
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9668
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9669
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9670
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9671
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9672
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9673
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9674
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9675
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9676
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9677
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9678
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9679
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9680
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9681
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9682
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9683
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9684
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9685
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9686
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9687
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9690
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9691
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9692
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9693
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9694
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9695
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9696
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9697
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9698
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9699
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9724
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9725
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9725
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9725
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9729
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9730
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9731
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9732
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9733
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9734
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9735
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9736
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9756
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9757
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9758
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9759
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9760
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9761
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9762
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9763
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9764
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9765
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9766
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9767
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9768
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9769
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9770
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9771
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9772
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9773
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9774
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9775
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9776
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9777
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9778
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9779
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9780
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9781
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9782
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9783
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9784
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9785
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9789
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9790
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9791
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9792
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9793
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9794
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9795
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9796
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9797
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9798
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9799
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9800
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,9801
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,9802
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,9831
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,9832
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,9832
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,9832
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,9851
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,9851
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,9852
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,9853
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,9853
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,9854
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,9855
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,9855
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,9856
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,9857
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,9857
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,9858
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,9859
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,9859
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,9860
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9861
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9862
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9863
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9864
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9865
0,2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484,9866
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9867
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9868
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9869
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9870
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9871
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9872
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9873
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9874
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9875
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9876
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9877
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9878
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9879
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9880
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9881
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9882
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9883
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9884
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9885
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9886
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9887
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9888
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9889
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9890
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9891
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9892
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9893
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9894
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9895
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9896
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9897
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9898
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,9899
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,9900
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,9901
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,9901
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,9901
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,9902
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,9902
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,9902
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9979
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9979
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9980
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9981
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9981
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9982
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9982
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9983
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9984
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9984
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9985
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9985
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9986
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9986
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9987
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9988
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9988
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9989
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9989
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9990
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9991
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9992
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9992
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9993
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9993
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,9994
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9995
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,9995
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,9996
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,9996
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10017
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10017
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10018
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10018
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10019
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10019
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10020
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10020
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10021
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10021
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10022
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10022
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10050
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10051
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10067
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10068
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10069
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10070
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10071
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10072
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,10278
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,10278
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,10280
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,10281
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,10284
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10345
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10346
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10347
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10348
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10348
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10349
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10350
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10350
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10351
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10352
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10352
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10353
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10354
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10354
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10355
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10356
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10356
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10357
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10358
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10358
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10359
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10360
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10360
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10361
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10362
1,1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987,10362
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,10363
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,10363
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,10363
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,10364
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,10365
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,10365
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,10366
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,10366
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,10367
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,10367
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,10368
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,10368
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,10369
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,10369
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10378
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10379
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10380
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10381
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10382
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10383
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10384
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10385
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10386
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10387
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10388
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10389
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10390
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10391
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10392
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10393
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10394
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10395
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10396
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10397
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10404
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10405
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10406
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10407
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10408
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10409
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10410
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10411
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10412
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10413
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10418
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10418
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10419
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10419
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10420
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10420
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10421
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10421
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10422
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10422
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10423
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10423
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,10424
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,10425
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,10426
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,10477
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10478
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10479
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10484
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10485
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10486
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10487
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,10488
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10489
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,10489
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10490
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,10490
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,10491
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10492
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,10492
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10493
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,10493
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,10494
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,10494
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,10495
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,10496
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,10496
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,10497
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10498
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10499
0,6404,27102076,EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27102076,10505
0,6404,27102076,EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27102076,10506
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,10517
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10517
0,286,,FDA.gov,http://www.fda.gov/,10518
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10519
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10520
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,10521
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10527
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10528
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10528
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10528
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,10529
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,10530
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10531
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,10531
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10532
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10532
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10533
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10534
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10535
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10536
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10537
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10538
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10539
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10540
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10541
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10542
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10542
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10543
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10543
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,10544
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,10545
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,10546
1,541,,,http://meetinglibrary.asco.org/content/105634-133,10546
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,10546
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,10548
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,10548
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,10550
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,10553
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,10553
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10554
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10554
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10555
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10555
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10556
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10556
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10557
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10557
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10558
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10558
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10559
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10559
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10560
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10560
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10561
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10561
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10562
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10562
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10563
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10563
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10564
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10564
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10565
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10565
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10566
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10566
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10567
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10567
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,10574
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10574
0,286,,FDA.gov,http://www.fda.gov/,10575
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10576
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10577
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,10578
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,10579
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,10579
0,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,10580
1,2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058,10580
2,2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999,10580
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10581
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10582
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,10583
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,10584
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10584
0,286,,FDA.gov,http://www.fda.gov/,10585
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10586
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10587
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,10588
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,10589
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,10589
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,10589
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10592
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10592
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10593
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10593
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10594
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10594
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10595
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10595
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10596
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10596
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10597
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10597
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,10598
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,10599
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,10600
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,10600
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,10601
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10602
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10603
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10604
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10619
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10620
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10621
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10621
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10622
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10622
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10623
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10624
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10633
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10634
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10634
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10635
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10635
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10636
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10637
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10638
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10639
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10640
0,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,10641
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10642
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10643
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10643
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10643
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10644
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10645
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10645
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10645
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10672
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10672
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10673
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10673
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,10674
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,10675
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,10676
0,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,10677
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10678
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10679
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10680
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,10681
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10682
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10682
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10683
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10683
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10684
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10684
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10685
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10685
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10686
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10686
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10687
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10687
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10688
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10688
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10689
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10689
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10690
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10690
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10691
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10691
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10692
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10692
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10693
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10693
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10694
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10694
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10695
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10695
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10696
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10696
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10697
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10697
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10698
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10698
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10699
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10699
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10700
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10700
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10701
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10701
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10702
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10702
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10703
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10703
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10704
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10704
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,10705
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,10705
0,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,10706
0,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,10711
1,3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549,10711
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10712
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10713
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10713
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10713
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10714
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10715
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10716
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10717
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10718
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10719
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10720
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10721
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10722
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10723
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10724
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10725
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10726
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10727
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10731
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10732
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10733
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10734
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10735
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10736
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10737
0,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,10738
0,2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853,10739
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10740
1,2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985,10740
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10761
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10761
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10761
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,10762
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,10763
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,10772
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,10772
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,10772
0,2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515,10773
1,2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389,10773
2,2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831,10773
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10774
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10774
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10774
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10775
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10775
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10775
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,10776
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,10777
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10778
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10778
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10779
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10779
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10780
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10780
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10781
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10781
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10782
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10782
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10783
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10783
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10784
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10785
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10786
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10787
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10788
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10789
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10790
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10791
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,10802
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,10803
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10808
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10809
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10810
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10811
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10812
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10813
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10814
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10815
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10816
0,6712,25971938,Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25971938,10817
1,7249,26798595,"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.",http://www.ncbi.nlm.nih.gov/pubmed/26798595,10817
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10818
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,10820
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10821
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10822
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10823
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10824
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10825
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10826
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10827
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10828
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10829
0,5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,10830
1,6326,26884591,What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).,http://www.ncbi.nlm.nih.gov/pubmed/26884591,10830
0,5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,10831
0,5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,10832
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10842
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10843
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,10844
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,10844
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,10845
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,10848
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,10848
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,10849
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10850
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10851
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10852
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10853
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10855
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10856
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10857
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10858
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10859
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10860
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10861
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10863
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10863
0,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,10864
1,2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206,10864
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,10870
0,571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170,10877
1,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,10877
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10878
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10879
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10880
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10881
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10882
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10883
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10884
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10885
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,10886
0,2006,23882082.0,"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",http://www.ncbi.nlm.nih.gov/pubmed/23882082,10891
1,7828,,"Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody",http://cancerres.aacrjournals.org/content/76/14_Supplement/1219,10891
0,2006,23882082.0,"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",http://www.ncbi.nlm.nih.gov/pubmed/23882082,10892
1,7828,,"Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody",http://cancerres.aacrjournals.org/content/76/14_Supplement/1219,10892
0,6712,25971938,Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25971938,10893
1,7249,26798595,"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.",http://www.ncbi.nlm.nih.gov/pubmed/26798595,10893
0,2006,23882082.0,"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",http://www.ncbi.nlm.nih.gov/pubmed/23882082,10894
1,7828,,"Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody",http://cancerres.aacrjournals.org/content/76/14_Supplement/1219,10894
0,6712,25971938,Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25971938,10895
1,7249,26798595,"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.",http://www.ncbi.nlm.nih.gov/pubmed/26798595,10895
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10898
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,10899
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10899
0,286,,FDA.gov,http://www.fda.gov/,10900
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10901
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,10902
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,10903
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10904
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10905
0,1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150,10906
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,10923
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10924
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,10924
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,10925
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,10925
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10926
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10927
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10927
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10927
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10928
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10929
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10930
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10931
0,1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351,10932
0,1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647,10933
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,10944
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,10945
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,10946
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,10947
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,10947
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,10948
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,10948
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,10949
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10958
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10958
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10958
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10959
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10959
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10959
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10960
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10960
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10960
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10961
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10961
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10961
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,10962
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,10962
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,10962
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,10965
0,561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146,10966
1,563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949,10966
2,564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166,10966
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,11186
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11187
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11188
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11189
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11189
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11189
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11190
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11190
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11190
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11191
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11191
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11191
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11192
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11192
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11192
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11193
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11193
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11193
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11194
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11194
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11194
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11195
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11195
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11195
0,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,11196
1,8568,21220471,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21220471,11196
0,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,11197
0,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,11198
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,11199
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,11199
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,11200
0,5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981,11201
1,5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479,11201
0,3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336,11202
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11203
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11203
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11204
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11204
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11205
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11205
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11206
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11206
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11207
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11207
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11208
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11208
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11209
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11209
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11210
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11210
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11211
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11211
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11212
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11212
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11218
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11219
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11219
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11220
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11220
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11221
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11221
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11222
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11222
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,11223
0,2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180,11224
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11225
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11225
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11225
0,59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228,11226
1,1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026,11226
2,1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259,11226
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,11229
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,11230
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11231
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11231
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11232
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11233
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11233
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11233
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11234
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11234
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11235
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11235
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11236
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11236
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11237
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11238
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11238
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11239
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11239
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11239
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11240
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11240
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11240
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11241
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11242
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11242
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11243
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11243
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11244
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11244
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11245
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11245
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11246
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11247
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11247
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11247
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11248
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11248
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11249
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11249
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11250
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11251
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11251
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11251
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11252
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11253
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11253
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11254
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11254
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11255
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11255
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11255
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11256
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11256
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11256
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11257
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11257
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11258
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11259
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11259
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11260
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11260
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11261
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11262
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11262
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11262
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11263
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11263
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11264
1,8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165,11264
2,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11264
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11265
1,8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390,11265
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11266
1,8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968,11266
0,982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748,11267
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11268
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11269
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11269
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11270
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11271
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11272
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11273
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11273
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11274
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11275
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11275
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11276
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11277
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11278
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11279
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11279
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11280
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11281
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11282
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11283
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11283
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11284
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11285
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11285
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11286
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11287
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11288
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11289
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11289
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11290
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11291
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11291
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11292
0,772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,11293
0,8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704,11294
1,8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308,11294
0,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,11295
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,11299
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,11300
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11305
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11309
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11310
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11311
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,11312
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11422
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11423
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11424
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11424
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11425
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11426
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11426
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11431
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11432
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11432
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11433
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11434
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11434
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11435
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11436
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11436
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11437
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11437
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11438
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11439
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11440
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11440
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11441
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11442
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11442
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11443
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11443
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11444
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11445
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11445
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11446
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11447
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11447
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11448
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11449
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11449
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11450
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11451
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11452
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11452
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11453
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11454
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11454
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11455
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11456
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11456
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11457
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11457
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11458
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11459
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11460
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11460
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11461
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11462
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11462
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11463
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11463
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11464
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11465
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11465
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11466
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11467
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11467
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11468
0,6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769,11469
0,104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432,11470
1,8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692,11470
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,11471
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,11471
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,11472
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,11472
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,11478
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,11479
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,11479
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,11479
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,11480
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,11481
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,12406
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12407
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12408
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12409
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12410
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12411
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12412
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12413
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12414
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,12415
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12416
1,4117,25514658,"Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.",http://www.ncbi.nlm.nih.gov/pubmed/25514658,12416
2,4556,26645196,Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/26645196,12416
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12417
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12417
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12418
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12419
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12420
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12420
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12421
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12421
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12421
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12422
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12423
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12424
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12425
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12426
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12426
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12426
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12427
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12427
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12428
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12429
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12430
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12430
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12430
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12431
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12431
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12432
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12433
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12434
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12434
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12434
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12435
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12436
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12437
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12437
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12438
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12439
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12439
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12439
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12440
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12441
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12441
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12442
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12443
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12444
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12444
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12445
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12445
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12445
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12446
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12447
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12448
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12449
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12450
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12451
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12451
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12451
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12452
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12452
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12453
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12453
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12454
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12455
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12455
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12455
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12456
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12457
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12458
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12459
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12459
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12460
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12461
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12461
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12461
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12462
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12463
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12463
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12464
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12465
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12466
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12466
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12466
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12467
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12468
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12469
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12470
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12470
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12470
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12471
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12471
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12472
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12473
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12473
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12474
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12475
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12476
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12477
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12477
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12477
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12478
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12479
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12480
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12481
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12481
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12481
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12482
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12482
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12483
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12483
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12483
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12484
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12485
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12486
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12486
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12487
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12488
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12489
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12490
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12491
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12491
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12491
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12492
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12492
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12493
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12494
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12494
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12495
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12496
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12496
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12496
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12497
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12498
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12499
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12499
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12499
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12500
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12500
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12501
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12502
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12503
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12504
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12504
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12504
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12505
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12506
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12507
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12507
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12508
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12508
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12509
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12509
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12509
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12510
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12511
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12512
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12513
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12514
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12515
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12515
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12516
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12517
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12517
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12517
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12518
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12519
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12519
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12519
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12520
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12521
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12521
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12522
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12523
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12523
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12524
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12525
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12526
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12526
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12526
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12527
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12528
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12528
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12529
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12530
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12530
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12530
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12531
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12532
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12533
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12534
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12535
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12535
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12535
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12536
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12537
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12537
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12538
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12539
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12540
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12540
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12540
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12541
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12541
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12542
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12543
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12544
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12545
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12545
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12545
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12546
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12546
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12547
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12548
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12549
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12550
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12551
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12551
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12551
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12552
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12552
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12553
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12553
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12553
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12554
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12554
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12555
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12556
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12557
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12558
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12559
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12560
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12560
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12561
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12562
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12562
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12562
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12563
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12564
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12564
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12564
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12565
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12566
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12567
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12567
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12568
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12568
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12568
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12569
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12570
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12571
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12572
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12572
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12573
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12574
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12575
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12576
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12576
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12577
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12577
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12577
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12578
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12579
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12580
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12580
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12581
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12582
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12582
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12582
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12583
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12584
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12584
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12585
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12585
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12585
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12586
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12587
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12588
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12589
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12590
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12590
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12591
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12592
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12592
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12592
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12593
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12594
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12595
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12595
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12596
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12596
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12596
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12597
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12598
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12599
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12600
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12600
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12600
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12601
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12601
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12602
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12603
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12603
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12603
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12604
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12604
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12605
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12606
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12607
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12608
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12609
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12610
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12610
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12611
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12611
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12611
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12612
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12613
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12614
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12614
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12615
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12616
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12616
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12616
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12617
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12618
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12618
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12618
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12619
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12620
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12621
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12622
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12622
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12623
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12624
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12625
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12625
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12626
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12627
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12627
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12627
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12628
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12629
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12629
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12629
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12630
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12631
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12631
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12632
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12633
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12633
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12633
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12634
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12635
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12635
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12636
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12637
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12638
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12639
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12640
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12641
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12641
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12641
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12642
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12642
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12643
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12643
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12644
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12644
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12644
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12645
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12646
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12647
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12648
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12649
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12650
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12651
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12651
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12651
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12652
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12652
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12653
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12654
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12654
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12655
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12656
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12657
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12657
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12657
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12658
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12658
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12659
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12659
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12659
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12660
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12661
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12662
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12663
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12664
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12665
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12666
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12666
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12667
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12667
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12667
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12668
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12668
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12668
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12669
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12670
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12671
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12672
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12672
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12673
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12674
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12674
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12675
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12675
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12675
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12676
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12677
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12678
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12679
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12679
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12679
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12680
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12681
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12681
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12682
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12683
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12684
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12685
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12686
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12686
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12687
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12687
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12687
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12688
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12688
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12689
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12690
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12690
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12690
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12691
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12692
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12693
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12693
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12694
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12694
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12694
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12695
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12696
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12697
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12698
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12698
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12698
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12699
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12700
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12701
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12701
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12702
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12703
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12703
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12703
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12704
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12705
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12705
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12706
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12707
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12708
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12708
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12709
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12710
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12710
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12710
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12711
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12712
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12713
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12714
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12714
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12715
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12715
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12715
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12716
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12717
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12718
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12719
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12719
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12719
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12720
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12720
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12721
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12722
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12723
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12724
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12724
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12725
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12725
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12725
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12726
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12727
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12728
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12728
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12729
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12730
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12731
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12731
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12731
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12732
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12733
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12733
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12734
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12735
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12736
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12736
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12736
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12737
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12738
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12739
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12740
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12741
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12741
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12742
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12742
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12742
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12743
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12743
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12744
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12744
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12744
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12745
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12746
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12747
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12748
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12748
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12748
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12749
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12750
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12750
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12751
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12752
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12753
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12753
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12753
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12754
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12755
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12755
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12756
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12757
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12758
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12758
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12759
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12760
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12761
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12761
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12761
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12762
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12763
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12763
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12763
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12764
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12764
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12765
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12766
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12767
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12768
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12769
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12769
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12769
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12770
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12771
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12772
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12772
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12773
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12774
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12774
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12775
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12776
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12777
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12777
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12777
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12778
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12778
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12779
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12779
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12779
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12780
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12781
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12782
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12783
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12784
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12784
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12784
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12785
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12785
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12786
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12787
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12788
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12789
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12789
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12789
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12790
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12790
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12791
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12792
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12793
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12793
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12793
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12794
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12795
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12795
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12796
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12797
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12798
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12798
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12798
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12799
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12799
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12800
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12801
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12802
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12803
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12804
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12804
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12804
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12805
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12806
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12807
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12807
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12808
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12809
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12810
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12811
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12811
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12811
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12812
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12812
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12813
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12813
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12813
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12814
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12815
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12816
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12817
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12817
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12818
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12818
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12819
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12820
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12821
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12822
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12822
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12822
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12823
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12824
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12825
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12825
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12825
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12826
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12826
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12827
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12828
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12828
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12829
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12830
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12830
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12830
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12831
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12832
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12833
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12833
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12834
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12835
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12836
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12836
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12836
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12837
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12838
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12839
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12839
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12839
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12840
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12841
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12841
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12842
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12843
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12844
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12844
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12844
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12845
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12846
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12847
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12847
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12848
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12848
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12849
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12849
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12849
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12850
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12851
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12852
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12853
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12853
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12854
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12854
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12854
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12855
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12856
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12857
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12858
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12859
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12860
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12861
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12861
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12862
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12862
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12862
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12863
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12863
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12863
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12864
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12865
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12865
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12866
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12867
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12868
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12869
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12869
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12869
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12870
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12870
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12871
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12872
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12873
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12874
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12874
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12875
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12876
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12877
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12877
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12877
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12878
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12878
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12878
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12879
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12880
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12881
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12882
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12882
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12883
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12883
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12883
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12884
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12885
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12886
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12886
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12887
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12888
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12889
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12890
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12890
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12890
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12891
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12891
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12892
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12893
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12894
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12894
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12894
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12895
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12896
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12897
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12897
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12898
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12898
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12899
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12900
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12900
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12900
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12901
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12902
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12903
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12904
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12904
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12904
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12905
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12906
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12906
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12907
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12908
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12908
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12909
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12910
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12911
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12912
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12912
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12912
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12913
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12913
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12914
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12915
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12916
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12916
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12916
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12917
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12918
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12918
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12918
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12919
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12920
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12921
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12922
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12922
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12923
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12923
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12924
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12925
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12926
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12927
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12927
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12927
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12928
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12929
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12930
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12930
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12931
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12931
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12931
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12932
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12933
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12933
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12934
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12935
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12936
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12936
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12936
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12937
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12938
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12939
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12940
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12941
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12941
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12942
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12942
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12942
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12943
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12944
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12944
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12945
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12946
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12947
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12947
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12947
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12948
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12949
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12949
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12949
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12950
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12950
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12951
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12952
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12953
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12954
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12954
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12955
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12955
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12955
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12956
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12957
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12958
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12958
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12958
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12959
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12960
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12961
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12962
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12962
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12963
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12964
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12965
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12966
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12966
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12967
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12967
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12967
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12968
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12968
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12968
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12969
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12969
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12970
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12971
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12972
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12973
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12974
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12975
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12975
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12976
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12976
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12976
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12977
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12978
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12979
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12979
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12979
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12980
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12981
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12982
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12982
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12983
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12983
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12984
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12985
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12986
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12986
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12986
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12987
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12988
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12988
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12989
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12990
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12991
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12992
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12992
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12992
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12993
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12994
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12995
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,12996
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,12996
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,12997
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,12997
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12997
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,12998
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,12999
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13000
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13000
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13001
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13002
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13002
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13002
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13003
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13004
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13005
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13006
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13006
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13006
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13007
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13007
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13008
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13008
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13009
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13010
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13010
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13010
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13011
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13012
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13013
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13014
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13015
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13015
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13015
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13016
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13017
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13017
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13018
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13018
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13019
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13020
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13021
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13022
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13022
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13022
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13023
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13023
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13023
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13024
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13025
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13025
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13026
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13027
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13028
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13029
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13030
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13030
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13031
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13032
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13032
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13032
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13033
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13034
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13034
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13034
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13035
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13035
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13036
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13037
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13038
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13038
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13038
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13039
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13040
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13040
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13041
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13042
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13043
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13043
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13043
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13044
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13045
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13045
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13046
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13047
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13048
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13049
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13050
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13050
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13050
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13051
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13051
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13052
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13053
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13053
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13054
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13054
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13054
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13055
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13056
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13057
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13058
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13058
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13058
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13059
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13060
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13060
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13061
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13062
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13063
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13064
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13065
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13066
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13066
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13067
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13067
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13067
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13068
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13068
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13069
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13070
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13071
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13072
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13072
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13072
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13073
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13074
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13074
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13075
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13076
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13077
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13077
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13077
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13078
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13078
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13079
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13080
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13081
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13082
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13082
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13082
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13083
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13084
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13084
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13085
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13086
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13087
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13087
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13087
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13088
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13089
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13089
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13089
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13090
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13091
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13091
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13092
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13093
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13094
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13095
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13096
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13096
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13097
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13097
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13097
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13098
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13098
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13098
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13099
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13100
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13101
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13101
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13102
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13103
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13104
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13105
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13106
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13106
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13107
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13107
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13107
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13108
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13108
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13109
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13110
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13111
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13111
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13111
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13112
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13113
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13114
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13114
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13114
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13115
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13116
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13116
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13117
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13118
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13119
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13119
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13120
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13120
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13120
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13121
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13122
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13123
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13124
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13125
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13125
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13126
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13126
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13126
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13127
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13128
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13128
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13129
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13130
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13131
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13132
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13132
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13132
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13133
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13133
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13134
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13135
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13135
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13135
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13136
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13137
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13138
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13138
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13139
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13139
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13139
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13140
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13141
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13142
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13143
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13144
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13145
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13145
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13145
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13146
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13146
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13147
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13148
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13149
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13149
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13149
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13150
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13151
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13151
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13152
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13153
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13153
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13154
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13155
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13156
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13156
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13156
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13157
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13158
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13159
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13160
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13160
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13160
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13161
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13162
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13162
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13163
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13163
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13164
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13164
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13164
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13165
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13166
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13167
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13168
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13169
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13170
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13170
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13171
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13172
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13172
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13172
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13173
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13173
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13174
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13175
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13176
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13176
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13176
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13177
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13178
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13178
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13179
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13180
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13181
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13182
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13182
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13182
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13183
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13184
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13185
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13186
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13186
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13186
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13187
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13187
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13188
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13189
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13190
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13191
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13191
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13191
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13192
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13192
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13193
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13193
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13194
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13195
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13196
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13196
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13196
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13197
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13198
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13198
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13199
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13200
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13201
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13202
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13202
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13202
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13203
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13204
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13205
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13205
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13206
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13207
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13207
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13207
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13208
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13208
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13209
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13210
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13211
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13211
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13211
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13212
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13213
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13213
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13213
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13214
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13214
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13215
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13216
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13217
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13218
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13218
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13218
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13219
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13220
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13221
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13221
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13222
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13223
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13224
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13224
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13225
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13226
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13227
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13227
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13227
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13228
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13228
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13229
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13230
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13231
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13231
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13231
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13232
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13233
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13234
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13234
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13235
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13236
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13237
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13237
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13237
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13238
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13239
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13240
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13241
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13241
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13241
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13242
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13242
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13243
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13244
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13244
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13244
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13245
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13246
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13247
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13247
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13248
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13248
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13249
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13250
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13250
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13250
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13251
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13252
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13253
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13254
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13254
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13254
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13255
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13255
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13256
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13257
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13258
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13259
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13260
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13260
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13261
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13262
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13262
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13262
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13263
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13264
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13265
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13265
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13266
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13267
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13267
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13267
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13268
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13269
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13270
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13270
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13270
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13271
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13272
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13272
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13273
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13274
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13274
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13274
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13275
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13276
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13277
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13277
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13278
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13278
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13278
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13279
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13280
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13280
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13281
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13282
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13283
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13283
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13283
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13284
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13284
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13285
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13286
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13287
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13288
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13289
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13290
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13290
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13290
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13291
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13292
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13292
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13293
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13294
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13295
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13295
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13296
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13297
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13297
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13297
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13298
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13298
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13299
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13300
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13301
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13302
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13302
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13302
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13303
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13304
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13304
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13305
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13306
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13307
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13307
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13307
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13308
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13309
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13310
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13311
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13311
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13311
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13312
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13312
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13313
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13314
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13314
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13315
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13316
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13317
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13317
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13317
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13318
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13319
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13319
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13319
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13320
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13321
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13321
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13322
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13323
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13324
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13325
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13325
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13326
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13327
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13327
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13327
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13328
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13328
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13328
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13329
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13330
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13330
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13331
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13332
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13333
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13334
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13334
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13335
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13336
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13337
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13337
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13337
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13338
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13339
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13339
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13339
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13340
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13341
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13342
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13342
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13343
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13344
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13344
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13345
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13345
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13345
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13346
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13347
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13348
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13349
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13349
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13349
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13350
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13350
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13351
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13352
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13353
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13354
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13354
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13355
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13356
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13356
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13356
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13357
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13358
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13359
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13360
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13361
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13361
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13361
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13362
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13362
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13363
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13363
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13363
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13364
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13364
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13365
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13366
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13367
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13368
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13368
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13369
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13370
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13371
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13372
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13372
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13372
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13373
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13374
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13375
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13376
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13376
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13376
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13377
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13377
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13378
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13379
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13380
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13380
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13380
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13381
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13381
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13382
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13383
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13383
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13383
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13384
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13384
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13385
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13386
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13387
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13388
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13388
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13389
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13390
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13391
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13392
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13392
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13392
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13393
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13394
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13395
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13396
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13396
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13397
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13397
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13397
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13398
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13399
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13400
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13401
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13401
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13401
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13402
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13402
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13403
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13403
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13403
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13404
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13405
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13406
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13406
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13407
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13408
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13409
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13410
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13411
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13411
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13411
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13412
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13412
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13413
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13414
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13415
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13415
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13416
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13416
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13416
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13417
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13418
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13419
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13420
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13420
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13421
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13421
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13421
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13422
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13423
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13423
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13423
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13424
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13425
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13426
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13427
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13427
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13428
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13428
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13428
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13429
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13430
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13431
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13431
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13432
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13433
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13433
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13433
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13434
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13435
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13436
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13437
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13437
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13438
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13439
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13440
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13440
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13441
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13442
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13442
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13442
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13443
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13444
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13445
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13445
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13446
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13446
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13446
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13447
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13448
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13449
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13450
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13451
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13451
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13451
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13452
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13452
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13453
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13454
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13454
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13455
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13455
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13455
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13456
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13457
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13458
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13458
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13458
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13459
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13460
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13461
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13462
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13462
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13463
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13464
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13464
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13464
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13465
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13466
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13466
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13467
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13468
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13469
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13469
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13469
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13470
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13471
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13471
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13472
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13473
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13473
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13474
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13475
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13476
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13477
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13477
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13477
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13478
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13478
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13479
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13479
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13479
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13480
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13481
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13482
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13483
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13483
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13484
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13485
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13485
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13485
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13486
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13487
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13488
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13488
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13489
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13490
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13490
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13490
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13491
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13492
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13493
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13494
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13495
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13495
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13496
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13496
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13496
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13497
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13498
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13499
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13500
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13501
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13501
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13502
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13502
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13502
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13503
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13504
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13504
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13504
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13505
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13505
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13506
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13507
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13508
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13509
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13510
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13510
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13510
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13511
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13511
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13512
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13513
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13514
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13515
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13515
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13516
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13516
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13516
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13517
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13518
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13518
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13519
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13520
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13521
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13521
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13521
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13522
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13523
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13524
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13525
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13525
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13525
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13526
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13527
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13527
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13528
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13528
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13529
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13530
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13530
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13530
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13531
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13532
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13533
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13533
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13534
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13535
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13535
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13535
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13536
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13537
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13538
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13539
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13539
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13539
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13540
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13541
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13541
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13542
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13543
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13543
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13544
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13545
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13545
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13545
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13546
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13547
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13548
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13549
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13550
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13550
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13551
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13551
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13551
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13552
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13553
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13553
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13554
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13555
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13555
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13555
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13556
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13557
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13558
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13559
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13559
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13560
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13561
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13562
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13562
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13562
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13563
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13564
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13564
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13565
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13566
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13567
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13567
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13567
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,13568
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,13569
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,13569
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13569
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13570
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,13571
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,13572
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,13572
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,13573
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,13573
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13574
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13575
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13576
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13577
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13578
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13579
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13580
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13581
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13582
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13583
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13584
0,2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198,13585
0,3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533,13586
1,3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016,13586
0,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,13599
1,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,13599
0,286,,FDA.gov,http://www.fda.gov/,13600
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,13601
0,447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124,13602
0,2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203,13603
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,13604
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,13605
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,13605
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,13606
0,2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837,13607
1,2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169,13607
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13809
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13810
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13811
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13812
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13812
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13813
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13814
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13814
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13815
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13816
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13821
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13822
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13823
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13824
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13824
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13825
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13826
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13827
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13828
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13828
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13841
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13842
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13843
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13843
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13844
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13845
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13846
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13847
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13847
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13848
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13849
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13850
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13851
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13851
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13852
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13853
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13854
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13855
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13855
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13856
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13857
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13858
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13859
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13860
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13860
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13861
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13862
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13862
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13863
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13864
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13865
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13866
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13867
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13868
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13868
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13869
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13870
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13870
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13871
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13872
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13873
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13874
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13874
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13875
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13876
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13877
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13878
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13878
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13879
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13880
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13881
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13882
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13882
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13883
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13884
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13885
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13886
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13886
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13887
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13888
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13889
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13889
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13890
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13891
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13892
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13893
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13894
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13895
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13896
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13896
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13897
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13897
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13898
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13899
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13900
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13901
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13901
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13902
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13903
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13904
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13905
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13906
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13907
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13908
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13908
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13909
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13910
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13911
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13912
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13912
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13913
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13914
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13915
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13915
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13916
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13917
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13917
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13918
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13919
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13920
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13921
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13922
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13923
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13923
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13924
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13925
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13926
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13926
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13927
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13928
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13929
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13929
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13930
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13931
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13932
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13933
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13934
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13935
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13935
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13936
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13937
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13938
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13939
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13939
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13940
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13941
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13941
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13942
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13943
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13944
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13945
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13945
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13946
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13947
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13948
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13949
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13950
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13951
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13951
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13952
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13953
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13954
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13955
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13956
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13956
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13961
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13961
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13962
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13963
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13964
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13997
1,2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574,13997
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,13998
0,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,13999
0,2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550,14000
0,9409,23536011,Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23536011,14001
1,9410,27223434,"Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.",http://www.ncbi.nlm.nih.gov/pubmed/27223434,14001
0,9409,23536011,Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23536011,14002
1,9410,27223434,"Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.",http://www.ncbi.nlm.nih.gov/pubmed/27223434,14002
0,9410,27223434,"Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.",http://www.ncbi.nlm.nih.gov/pubmed/27223434,14003
0,9409,23536011,Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23536011,14004
0,4894,18536917,The E75 HER2/neu peptide vaccine.,http://www.ncbi.nlm.nih.gov/pubmed/18536917,14006
0,2627,24959084,The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24959084,14009
0,2627,24959084,The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24959084,14012
0,2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538,14016
0,9557,28520362,,http://www.ncbi.nlm.nih.gov/pubmed/28520362,14017
1,9558,28520364,,http://www.ncbi.nlm.nih.gov/pubmed/28520364,14017
2,9559,25398397,"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.",http://www.ncbi.nlm.nih.gov/pubmed/25398397,14017
0,4894,18536917,The E75 HER2/neu peptide vaccine.,http://www.ncbi.nlm.nih.gov/pubmed/18536917,14018
0,9560,26260909,Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26260909,14019
1,9561,24367169,Lapatinib: new opportunities for management of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24367169,14019
0,9563,25800760,Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25800760,14020
1,9587,28710747,Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28710747,14020
2,9588,28284008,Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/28284008,14020
0,9588,28284008,Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/28284008,14021
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,14022
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,14022
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,14023
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,14023
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14024
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14054
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14055
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14056
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14057
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14058
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14059
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14060
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14061
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14062
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14063
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14064
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14065
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14066
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14067
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14068
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14069
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14070
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14071
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14072
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14073
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14074
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14075
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14076
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14077
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14078
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14079
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14080
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14081
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14082
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14083
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14084
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14085
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14086
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14087
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14088
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14089
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14090
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14091
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14092
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14093
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14094
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14095
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14096
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14097
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14098
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14099
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14100
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14101
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14102
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14103
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14104
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14105
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14106
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14107
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14108
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14109
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14110
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14111
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14112
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14113
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14114
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14115
0,1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156,14116
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14294
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14295
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14295
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14296
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14297
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14297
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14298
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14298
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14298
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14299
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14299
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14300
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14300
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14301
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14301
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14301
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14302
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14303
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14303
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14304
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14305
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14305
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14306
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14306
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14306
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14307
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14307
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14307
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14308
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14309
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14309
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14310
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14310
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14311
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14311
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14312
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14312
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14312
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14313
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14314
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14314
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14315
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14315
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14315
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14316
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14316
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14317
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14317
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14318
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14319
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14319
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14319
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14320
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14321
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14321
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14322
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14322
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14323
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14323
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14324
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14324
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14325
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14325
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14325
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14326
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14327
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14327
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14328
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14328
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14328
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14329
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14330
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14330
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14351
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14351
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14352
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14352
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14352
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14353
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14354
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14354
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14355
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14356
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14356
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14357
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14357
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14358
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14358
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14358
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14359
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14359
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14360
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14360
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14361
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14362
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14362
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14362
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14371
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14371
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14372
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14372
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14373
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14373
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14373
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14374
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14379
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14379
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14380
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14380
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14381
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14382
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14382
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14382
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14383
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14383
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14384
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14384
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14385
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14386
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14386
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14386
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14387
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14387
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14387
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14388
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14389
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14389
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14390
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14390
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14395
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14395
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14396
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14396
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14396
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14397
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14397
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14398
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14399
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14399
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14399
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14400
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14401
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14401
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14402
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14402
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14403
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14403
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14403
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14404
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14404
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14405
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14406
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14406
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14407
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14407
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14407
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14408
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14409
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14409
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14410
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14410
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14411
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14411
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14412
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14412
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14413
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14414
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14414
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14414
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14415
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14415
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14416
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14416
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14417
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14417
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14417
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14418
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14419
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14419
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14420
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14421
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14421
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14421
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14422
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14422
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14423
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14423
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14423
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14424
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14424
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14425
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14426
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14426
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14427
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14428
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14428
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14429
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14429
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14430
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14430
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14430
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14431
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14431
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14431
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14432
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14433
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14433
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14434
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14434
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14439
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14440
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14440
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14440
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14441
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14441
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14442
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14442
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14443
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14443
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14444
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14444
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14445
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14445
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14445
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14446
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14447
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14447
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14448
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14448
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14449
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14449
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14449
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14450
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14451
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14451
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14452
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14453
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14453
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14453
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14454
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14454
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14455
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14455
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14455
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14456
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14456
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14457
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14458
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14458
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14463
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14463
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14463
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14464
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14464
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14465
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14465
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14466
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14467
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14467
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14468
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14468
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14468
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14469
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14469
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14470
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14471
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14471
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14472
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14472
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14473
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14474
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14474
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14474
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14475
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14476
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14476
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14477
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14477
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14478
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14478
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14478
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14479
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14479
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14480
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14480
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14481
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14482
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14482
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14482
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14487
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14487
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14488
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14489
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14489
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14489
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14490
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14490
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14491
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14491
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14491
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14492
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14492
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14493
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14494
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14494
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14495
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14495
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14496
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14496
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14496
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14497
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14498
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14498
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14499
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14499
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14500
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14500
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14501
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14501
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14501
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14503
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14503
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14503
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14504
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14505
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14505
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14506
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14506
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14511
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14512
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14512
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14513
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14513
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14513
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14514
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14514
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14515
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14515
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14516
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14517
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14517
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14517
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14518
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14518
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14519
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14520
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14520
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14521
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14521
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14521
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14522
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14522
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14523
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14524
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14524
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14525
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14525
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14526
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14526
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14526
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14527
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14528
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14528
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14529
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14529
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14529
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14530
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14530
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14539
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14539
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14540
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14540
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14541
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14542
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14542
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14542
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14547
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14547
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14548
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14548
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14549
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14549
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14549
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14550
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14551
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14551
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14552
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14553
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14553
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14554
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14554
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14554
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14555
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14556
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14556
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14556
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14557
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14557
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14558
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14558
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14559
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14559
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14560
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14560
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14560
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14561
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14561
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14562
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14563
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14563
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14563
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14564
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14564
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14565
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14565
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14566
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14567
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14567
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14568
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14568
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14568
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14569
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14569
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14570
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14571
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14572
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14572
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14573
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14573
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14573
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14574
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14574
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14579
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14580
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14580
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14581
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14581
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14582
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14582
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14582
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14591
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14591
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14592
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14592
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14593
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14593
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14593
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14594
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14595
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14595
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14596
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14596
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14597
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14598
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14598
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14598
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14599
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14600
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14600
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14601
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14601
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14602
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14602
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14602
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14607
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14607
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14608
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14609
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14609
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14609
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14610
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14610
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14611
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14611
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14612
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14612
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14613
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14613
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14613
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14614
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14615
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14615
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14616
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14616
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14617
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14617
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14617
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14618
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14619
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14619
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14620
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14620
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14620
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14621
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14622
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14622
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14623
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14623
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14624
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14625
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14625
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14626
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14626
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14626
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14639
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14639
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14640
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14640
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14641
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14642
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14642
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14642
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14643
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14643
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14644
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14644
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14645
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14646
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14646
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14646
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14647
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14648
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14648
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14649
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14649
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14649
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14650
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14650
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14651
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14651
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14652
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14652
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14652
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14653
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14654
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14654
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14660
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,14660
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14660
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14661
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14661
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14662
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14663
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14664
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14664
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14664
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14665
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,14665
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14665
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14666
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14666
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14667
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14668
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14669
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14669
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14669
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14670
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,14670
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14670
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14671
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14671
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14672
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14673
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14674
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14674
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14674
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14675
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,14675
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14675
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14676
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14676
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14677
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14678
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14679
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14679
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14679
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14680
1,467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338,14680
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14680
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14681
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14681
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14682
0,468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011,14683
0,222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808,14684
1,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14684
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14684
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14686
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14687
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14688
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14689
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14690
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14691
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14692
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14693
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14698
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14698
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14698
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14699
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14699
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14700
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14700
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14701
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14701
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14701
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14702
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14702
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14703
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14703
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,14712
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,14713
0,2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775,14714
0,1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404,14715
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,14716
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,14716
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,14717
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,14717
0,137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657,14718
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,14719
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,14721
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,14721
0,1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174,14722
1,1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962,14722
2,9868,25317746,Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25317746,14722
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14724
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14725
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14725
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14726
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14726
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14726
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14727
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14727
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14728
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14728
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14728
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14729
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14729
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14730
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14730
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14731
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14736
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14736
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14737
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14737
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14738
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14738
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14738
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14739
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14739
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14740
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14740
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14740
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14741
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14741
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14742
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14742
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14743
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14743
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14743
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14744
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14744
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14748
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14748
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14748
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14749
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14749
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14750
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14750
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14751
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14751
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14751
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14752
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14752
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14753
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14753
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14754
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14754
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14755
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14755
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14755
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14756
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14756
0,1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539,14757
1,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,14757
2,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14757
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14758
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14758
0,7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985,14759
1,9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297,14759
0,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,14760
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,14761
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,14762
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,14763
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,14764
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,14765
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,14766
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,14767
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,14768
0,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,14828
1,2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539,14828
2,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,14828
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,14829
0,2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938,14830
0,348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154,14831
0,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,14832
1,4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636,14832
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15267
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15764
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15765
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15765
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15766
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15767
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15768
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15769
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15769
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15770
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15770
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15770
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15771
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15771
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15772
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15773
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15774
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15775
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15775
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15776
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15777
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15777
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15777
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15778
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15779
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15780
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15780
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15781
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15782
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15782
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15782
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15783
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15784
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15784
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15785
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15786
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15787
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15787
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15788
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15788
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15789
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15790
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15790
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15790
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15791
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15792
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15793
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15793
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15794
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15795
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15795
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15796
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15797
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15797
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15797
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15798
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15799
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15800
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15801
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15801
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15801
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15802
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15802
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15803
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15804
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15804
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15805
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15806
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15806
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15807
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15807
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15807
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15808
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15809
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15809
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15810
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15811
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15812
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15813
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15814
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15815
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15815
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15816
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15816
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15817
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15818
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15819
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15819
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15819
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15820
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15821
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15822
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15822
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15822
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15823
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15823
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15824
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15825
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15825
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15826
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15827
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15827
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15827
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15828
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15828
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15829
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15829
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15830
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15831
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15832
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15833
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15834
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15835
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15836
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15836
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15837
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15838
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15839
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15839
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15839
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15840
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15840
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15841
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15841
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15841
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15842
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15843
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15844
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15845
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15845
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15846
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15847
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15847
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15848
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15848
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15849
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15849
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15850
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15851
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15852
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15853
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15853
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15853
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15854
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15855
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15855
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15856
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15856
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15856
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15857
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15858
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15859
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15860
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15860
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15861
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15862
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15863
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15864
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15865
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15865
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15866
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15867
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15867
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15868
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15868
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15868
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15869
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15870
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15871
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15872
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15872
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15873
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15874
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15874
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15875
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15875
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15875
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15876
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15876
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15877
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15878
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15879
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15879
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15879
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15880
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15880
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15881
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15882
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15883
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15883
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15884
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15885
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15885
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15885
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15886
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15887
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15888
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15888
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15889
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15890
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15891
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15891
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15892
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15892
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15893
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15894
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15895
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15895
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15895
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15896
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15897
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15898
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15899
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15900
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15901
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15901
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15902
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15902
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15902
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15903
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15903
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15904
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15905
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15906
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15906
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15907
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15908
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15908
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15909
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15909
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15909
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15910
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15911
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15911
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15911
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15912
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15913
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15913
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15914
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15915
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15916
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15917
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15917
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15918
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15918
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15918
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15919
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15920
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15921
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15922
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15923
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15923
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15924
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15924
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15925
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15925
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15926
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15927
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15928
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15928
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15929
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15930
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15930
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15930
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15931
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15932
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15933
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15933
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15934
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15935
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15935
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15936
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15937
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15937
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15937
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15938
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15939
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15939
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15940
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15941
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15941
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15942
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15942
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15942
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15943
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15944
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15945
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15946
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15947
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15947
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15947
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15948
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15949
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15950
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15951
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15951
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15952
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15952
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15953
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15954
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15954
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15955
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15955
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15955
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15956
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15957
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15958
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15958
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15959
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15960
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15961
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15961
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15962
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15963
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15964
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15964
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15965
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15965
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15965
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15966
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15967
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15967
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15967
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15968
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15969
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15969
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15970
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15971
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15972
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15972
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15973
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15974
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15974
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15974
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15975
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15976
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15977
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15977
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15978
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15979
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15979
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15980
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15981
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15981
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15982
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15983
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15984
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15984
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15985
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15985
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15985
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15986
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15987
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15988
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15989
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15989
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15990
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15990
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15991
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15992
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15993
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15993
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15993
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,15994
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,15995
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15996
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,15996
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15997
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,15998
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,15998
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,15999
1,541,,,http://meetinglibrary.asco.org/content/105634-133,15999
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,15999
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16000
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16001
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16002
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16003
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16003
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16004
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16005
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16005
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16006
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16007
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16007
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16007
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16008
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16009
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16010
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16011
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16012
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16012
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16012
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16013
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16013
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16014
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16014
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16015
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16016
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16017
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16018
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16019
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16020
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16020
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16021
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16021
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16022
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16022
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16022
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16023
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16023
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16024
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16025
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16026
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16027
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16027
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16028
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16028
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16028
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16029
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16030
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16030
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16030
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16031
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16032
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16033
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16034
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16034
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16035
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16035
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16036
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16037
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16038
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16038
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16039
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16040
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16040
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16040
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16041
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16042
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16043
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16043
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16044
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16044
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16045
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16046
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16046
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16047
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16048
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16049
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16049
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16049
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16050
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16051
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16051
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16052
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16053
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16054
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16054
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16055
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16056
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16057
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16057
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16057
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16058
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16059
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16060
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16061
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16062
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16062
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16063
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16063
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16063
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16064
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16064
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16065
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16066
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16066
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16066
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16067
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16067
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16068
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16069
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16069
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16070
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16071
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16072
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16073
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16073
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16074
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16074
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16074
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16075
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16075
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16076
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16077
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16078
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16079
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16080
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16080
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16081
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16082
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16082
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16083
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16083
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16083
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16084
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16085
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16086
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16087
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16087
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16088
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16089
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16089
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16090
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16090
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16090
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16091
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16092
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16093
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16093
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16093
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16094
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16094
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16095
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16096
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16097
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16097
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16098
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16099
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16100
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16100
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16101
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16102
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16102
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16103
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16104
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16105
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16106
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16106
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16106
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16107
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16107
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16108
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16109
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16110
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16110
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16111
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16112
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16113
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16113
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16113
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16114
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16115
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16115
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16116
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16117
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16118
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16118
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16118
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16119
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16120
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16120
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16121
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16122
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16123
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16123
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16124
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16125
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16126
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16126
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16127
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16127
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16127
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16128
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16128
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16129
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16130
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16130
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16131
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16131
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16131
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16132
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16133
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16134
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16135
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16135
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16136
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16137
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16138
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16138
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16139
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16139
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16139
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16140
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16141
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16142
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16142
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16143
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16144
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16145
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16146
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16147
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16147
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16148
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16148
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16148
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16149
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16150
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16151
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16151
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16152
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16152
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16153
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16154
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16154
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16154
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16155
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16156
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16157
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16157
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16158
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16159
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16160
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16160
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16160
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16161
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16162
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16162
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16163
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16164
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16165
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16165
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16165
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16166
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16166
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16167
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16168
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16169
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16169
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16170
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16171
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16172
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16172
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16172
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16173
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16174
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16175
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16175
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16176
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16176
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16177
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16177
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16178
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16178
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16179
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16180
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16181
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16181
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16181
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16182
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16183
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16184
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16184
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16185
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16185
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16185
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16186
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16187
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16188
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16188
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16189
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16190
0,9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361,16191
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16192
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16193
0,187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16194
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16195
1,9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501,16195
0,187,23934108.0,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108,16196
1,541,,,http://meetinglibrary.asco.org/content/105634-133,16196
2,542,23200175.0,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175,16196
0,1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111,16197
1,4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098,16197
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16198
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16198
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16199
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16200
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16201
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16202
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16203
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16204
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16205
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16205
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16206
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16207
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16207
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16208
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16209
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16210
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16211
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16212
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16213
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16213
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16214
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16215
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16216
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16217
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16217
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16218
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16219
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16220
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16220
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16221
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16222
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16223
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16224
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16225
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16225
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16226
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16227
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16227
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16228
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16229
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16230
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16231
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16232
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16233
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16233
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16234
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16235
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16236
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16236
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16237
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16238
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16239
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16240
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16241
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16241
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16242
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16243
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16243
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16244
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16245
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16246
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16247
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16247
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16248
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16249
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16250
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16251
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16252
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16253
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16253
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16254
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16254
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16255
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16256
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16257
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16258
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16258
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16259
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16260
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16261
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16262
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16263
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16264
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16264
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16265
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16266
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16266
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16267
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16268
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16269
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16270
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16271
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16272
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16272
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16273
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16274
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16274
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16275
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16276
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16277
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16278
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16279
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16279
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16280
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16281
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16282
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16283
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16283
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16284
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16285
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16286
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16287
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16287
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16288
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16289
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16290
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16291
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16292
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16293
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16293
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16294
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16295
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16295
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16296
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16297
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16298
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16299
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16299
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16300
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16301
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16302
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16302
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16303
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16304
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16305
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16306
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16307
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16308
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16308
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16309
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16310
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16311
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16312
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16313
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16313
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16314
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16315
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16315
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16316
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16317
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16318
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16319
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16320
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16321
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16321
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16322
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16323
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16324
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16325
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16325
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16326
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16327
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16327
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16328
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16329
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16330
0,2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975,16331
0,2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976,16332
0,2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407,16333
1,2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052,16333
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16335
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16336
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16337
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16338
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16339
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16340
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16341
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16342
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16343
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16344
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16345
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16346
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16347
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16348
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16349
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16350
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,16351
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,16351
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,16352
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,16352
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,16353
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,16353
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,16354
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,16354
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16355
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,16356
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,16356
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,16357
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,16357
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,16358
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16359
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,16359
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16360
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,16360
0,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,16361
1,2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292,16361
0,2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753,16362
1,3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443,16362
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16363
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16364
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16365
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16366
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16367
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16368
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16369
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16370
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16371
0,2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730,16372
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,16373
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16374
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,16374
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16375
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,16375
0,2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243,16376
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16377
1,2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246,16377
0,2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676,16378
1,2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611,16378
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16379
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16380
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16380
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16381
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16381
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16382
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16383
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16384
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16385
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16385
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16386
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16387
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16387
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16388
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16389
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16390
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16391
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16392
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16393
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16393
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16394
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16395
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16395
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16396
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16397
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16398
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16399
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16399
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16400
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16401
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16402
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16402
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16403
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16404
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16405
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16405
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16406
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16407
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16408
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16408
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16409
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16409
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16410
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16410
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16411
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16412
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16413
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16414
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16415
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16416
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16417
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16417
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16418
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16418
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16419
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16420
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16421
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16422
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16423
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16424
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16425
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16425
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16426
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16426
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16427
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16428
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16429
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16429
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16430
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16431
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16432
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16432
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16433
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16433
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16434
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16435
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16435
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16436
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16437
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16438
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16439
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16440
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16441
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16442
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16443
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16443
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16444
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16444
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16445
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16446
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16447
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16448
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16448
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16449
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16450
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16450
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16451
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16451
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16452
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16453
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16454
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16454
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16455
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16456
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16457
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16458
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16459
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16460
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16461
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16461
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16462
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16462
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16463
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16464
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16465
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16466
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16467
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16467
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16468
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16468
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16469
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16470
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16471
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16472
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16473
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16473
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16474
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16474
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16475
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16476
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16477
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16478
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16478
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16479
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16479
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16480
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16481
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16482
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16483
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16483
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16484
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16484
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16485
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16486
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16487
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16488
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16488
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16489
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16490
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16491
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16491
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16492
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16493
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16493
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16494
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16494
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16495
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16496
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16497
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16498
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16499
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16499
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16500
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16501
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16502
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16502
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16503
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16504
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16505
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16505
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16506
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16507
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16508
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16508
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16509
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16510
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16511
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16511
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16512
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16513
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16514
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16515
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16515
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16516
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16517
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16518
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16518
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16519
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16520
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16521
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16521
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16522
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16523
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16524
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16525
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16526
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16526
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16527
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16528
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16528
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16529
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16530
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16531
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16532
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16532
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16533
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16533
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16534
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16535
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16536
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16537
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16538
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16538
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16539
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16539
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16540
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16541
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16542
0,1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498,16543
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16544
1,8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593,16544
0,28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070,16545
1,1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574,16545
0,212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045,16546
0,510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475,16550
0,2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115,16551
